



ROPS & GRAY LLP  
PRUDENTIAL TOWER  
800 BOYLSTON STREET  
BOSTON, MA 02199-3600  
WWW.ROPSGRAY.COM

June 9, 2020

R. Daniel O'Connor  
T +1 617 951 7260  
daniel.oconnor@ropesgray.com

**BY FEDEX**

The Honorable Denise L. Cote  
United States District Court for the Southern District of New York  
500 Pearl St.  
New York, NY 10007

Re: Request for Restitution for *United States v. Nikas et al.*, 19-cr-716 (S.D.N.Y. filed Oct. 7, 2019)

Dear Judge Cote:

We write on behalf of Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”) to assert a claim for restitution for fees and expenses that Takeda incurred directly as a result of the criminal actions of Telemaque Lavidas (“Defendant”).

On January 15, 2020, a jury convicted Defendant of insider trading by illegally tipping co-defendant Georgios Nikas (“Co-Defendant Nikas”) with material, non-public information related to ARIAD Pharmaceuticals, Inc. (“ARIAD”) that Defendant received from his father, ARIAD board member Athanase Lavidas, on three occasions between 2013 and 2015. Co-Defendant Nikas subsequently traded on the information, and made several million in profits and avoided substantial losses.

On December 1, 2016, ARIAD received a grand jury subpoena from the U.S. Department of Justice (the “DOJ”) issued in connection with the DOJ’s investigation of insider trading of ARIAD securities, which compelled the production of, among other things, copious amounts of documents and communications relating to ARIAD’s board of directors (the “ARIAD Subpoena”) related to the current prosecution. ARIAD retained Gibson Dunn & Crutcher LLP (“Gibson Dunn”) to assist in responding to the ARIAD Subpoena.

Takeda acquired ARIAD in February 2017.<sup>1</sup> On or around November 14, 2019, Takeda as the successor to ARIAD received a grand jury subpoena (the “Takeda Subpoena,” together with the ARIAD Subpoena, the “Subpoenas”) from the DOJ issued in connection with Defendant’s criminal case, attached hereto as Exhibit 1. The Takeda Subpoena compelled the production of “any and all”

---

<sup>1</sup> Takeda Pharm. Co., Annual Report (Form 20-F), at 23 (June 27, 2019).

ROPES & GRAY LLP

(1) records and communications relating to training sessions and information provided to the ARIAD Board of Directors from 2013 through 2015 relating to (a) confidentiality; (b) material, non-public information; and/or (c) or insider trading; and (2) documents relating to approximately thirty different entries on a chronology of events submitted on June 11, 2014 to the United States Securities and Exchange Commission (the “SEC”) by ARIAD’s former counsel. The deadline for the Takeda Subpoena was November 20, 2019, an extremely tight turnaround given Defendant’s upcoming trial commencing on January 6, 2020.

For the reasons explained below, as a result of Defendant’s criminal activity and subsequent prosecution, Takeda experienced substantial, direct financial losses in responding to the Subpoenas.<sup>2</sup> Takeda is thus a victim of Defendant’s criminality under the Mandatory Victims Restitution Act (“MVRA”) and seeks restitution to recover for its losses. *See* 18 U.S.C. § 3663A(a)(2); *see also* *United States v. Kinney*, 610 F. App’x 49, 52 (2d Cir. 2015) (holding that the MVRA “makes a defendant convicted of an offense involving a criminal scheme liable for restitution to all persons harmed by his actions pursuant to that scheme”). In total, Takeda has incurred \$186,430.99 in fees and costs associated with the DOJ’s investigation and prosecution of Defendant.

Takeda incurred reasonable and necessary document review and production expenses in responding to the Subpoenas, as well as technical costs, such as forensic, data storage, and processing expenses.<sup>3</sup> *See* 18 U.S.C. § 3663A(b)(4). Defendant’s criminal activity was the “direct and proximate cause” of the expenses Takeda incurred in responding to the Subpoenas, as required by the MVRA and further clarified by the Second Circuit. *See* 18 U.S.C. § 3663A(a)(2); *see also* *United States v. Cean*, 771 F. App’x 81, 83 (2d Cir. 2019) (“As to proximate cause, the basic question is whether the harm alleged has a sufficiently close connection to the conduct at issue—i.e., whether it is foreseeable.”); *United States v. Odiase*, 788 F. App’x 760, 764 (2d Cir. 2019) (“Where the crime of conviction is a conspiracy, a district court may order the defendant to pay restitution for the reasonably foreseeable losses caused by the conspiracy.”). Indeed, but for Defendant’s criminal activity, Takeda would not have incurred any expenses in responding to the Subpoenas issued in connection with Defendant’s prosecution by the DOJ. This District has ordered convicted defendants to pay restitution to companies that assisted with the defendants’ prosecutions in similar circumstances. *See, e.g.*, *United States v. Afriyie*, No. 16-CR-377-PAE, 2020 WL 634425, at \*1-2 (S.D.N.Y. Feb. 11, 2020) (finding that the MVRA required the defendant in an insider trading scheme to compensate one of the victims, his former employer, for “attorney’s fees that [his employer] was required to incur to advance the investigation or prosecution of the offense”); *cf. United States v. Lagos*, 138 S. Ct. 1684, 1686 (2018) (clarifying that the MVRA applies to “government investigations and criminal proceedings,” but not to private investigations).

Takeda incurred substantial time, effort, and expense in responding to this matter. All told, Takeda made six productions of documents to the DOJ in response to the ARIAD Subpoena and four productions of documents to the DOJ in response to the Takeda Subpoena. In order to respond to the

---

<sup>2</sup> By virtue of its acquisition of ARIAD, Takeda has assumed the fees and costs associated with the ARIAD Subpoena.

<sup>3</sup> Takeda is only requesting restitution for its legal fees previously mentioned and not the costs incurred by Takeda’s employees in responding to the Subpoena.

ROPS & GRAY LLP

Takeda Subpoena, Takeda first had to identify and ensure the preservation of the email archives of 42 different ARIAD custodians with possession of potentially responsive material dating back to 2013—only three of whom are still current employees. These efforts were further complicated by Takeda's complex corporate history. In 2017, Takeda acquired ARIAD. Then, in 2019, Takeda merged with Shire, a transformational event for both corporations and for which efforts to integrate technology and computer infrastructure are still ongoing. In tandem with these e-discovery preservation efforts, Takeda also contacted its former counsel to collect and review potentially responsive information that was previously produced to the SEC and DOJ in 2013 and 2014 in an effort to leverage existing work product and to produce documents to the DOJ as expeditiously as possible.

There were extensive costs in connection with responding to the Subpoenas related to the document production, including attorney time spent collecting documents, reviewing the collected materials for responsiveness, privilege, and for proprietary information, as well as discussing the scope of the Subpoenas and materials to be produced with the DOJ.

Takeda took extensive efforts to limit all of those expenditures by attempting to have in-house counsel complete much of the work in gathering responsive materials and, for the Takeda Subpoena, to collect existing work produced by former counsel. Takeda ultimately required the assistance of outside counsel to assist with document review and production, as well as to interface with the DOJ. ARIAD retained Gibson Dunn and Takeda retained Ropes & Gray to assist with responding to the Subpoenas. Ropes & Gray worked with the DOJ on multiple calls to significantly limit the scope of the original requests in the Takeda Subpoena and focus to the extent possible on what the DOJ most needed for its trial efforts, and, through these efforts, substantially limited the costs and expenses necessary for the response. Ropes & Gray's fees and associated costs, totaling \$145,224, are set forth in Exhibit 2. Gibson Dunn's fees and associated costs in connection with the ARIAD Subpoena, totaling \$41,206.99, are set forth in Exhibit 3.

Please contact me if I can further clarify anything in this letter or answer your questions.

Best regards,



R. Daniel O'Connor

Enclosures

cc: Chris Allen, Vice President, Head Counsel, U.S. Litigation & Investigation, Takeda Pharmaceuticals U.S.A., Inc.  
Melanie Nevin, Counsel, Takeda Pharmaceuticals U.S.A., Inc.  
Daniel Tracer & Richard Cooper, Assistant United States Attorneys  
United States Probation and Pretrial Services Office

# Exhibit 1

## Grand Jury Subpoena



**U.S. Department of Justice**  
*United States Attorney*  
*Southern District of New York*

*The Silvio J. Mollo Building*  
*One Saint Andrew's Plaza*  
*New York, New York 10007*

November 14, 2019

**BY EMAIL**

Takeda Pharmaceuticals U.S.A., Inc.  
c/o Chris Allen, Esq.  
One Takeda Parkway  
Deerfield, IL 60015

Dear Madam or Sir:

**Re: Grand Jury Subpoena**

Please be advised that the accompanying grand jury subpoena has been issued in connection with an official criminal investigation of a suspected felony being conducted by a federal grand jury. The Government hereby requests that you voluntarily refrain from disclosing the existence of the subpoena to any third party. While you are under no obligation to comply with our request, we are requesting you not to make any disclosure in order to preserve the confidentiality of the investigation and because disclosure of the existence of this investigation might interfere with and impede the investigation.

Moreover, if you intend to disclose the existence of this subpoena to a third party, please let me know before making any such disclosure.

Thank you for your cooperation in this matter.

Very truly yours,

AUDREY STRAUSS  
*Attorney for the United States,  
Acting Under Authority  
Conferred by 28 U.S.C. § 515*

By:   
Richard Cooper/Daniel Tracer  
Assistant United States Attorneys  
(212) 637-1027/2329

Grand Jury Subpoena

United States District Court  
SOUTHERN DISTRICT OF NEW YORK

TO: Takeda Pharmaceuticals U.S.A., Inc.  
c/o Chris Allen, Esq.  
One Takeda Parkway  
Deerfield, IL 60015

GREETINGS:

WE COMMAND YOU that all and singular business and excuses being laid aside, you appear and attend before the GRAND JURY of the people of the United States for the Southern District of New York, at the United States Courthouse, 40 Foley Square, Room 220, in the Borough of Manhattan, City of New York, in the Southern District of New York, at the following date, time and place:

Appearance Date: November 20, 2019

Appearance Time: 10:00 a.m.

to testify and give evidence in regard to an alleged violation of:

18 U.S.C. §§ 1956(a)(1)(A), 1956(a)(1)(B), 1957, 371, 1341, 1343, and 1348; 15 U.S.C. § 78j(b) and 17 C.F.R. § 240.10b-5

and not to depart the Grand Jury without leave thereof, or of the United States Attorney, and that you bring with you and produce at the above time and place the following:

See Attached Rider


Please produce the requested information (1) on or before the return date to Richard Cooper, Assistant United States Attorney, Southern District of New York, One Saint Andrews Plaza, New York, NY 10007 and SA Matthew Mahaffey at: Federal Bureau of Investigation, 26 Federal Plaza, New York, NY 10278, and, if possible, by email to Richard.cooper@usdoj.gov and mdmahaffey@fbi.gov, tel. 212-637-1027 (Cooper) and 212-384-2110 (Mahaffey); and (2) accompanied by an executed copy of the attached Declaration of Custodian of Records. PLEASE PROVIDE MATERIALS ELECTRONICALLY IF POSSIBLE.

Failure to attend and produce any items hereby demanded will constitute contempt of court and will subject you to civil sanctions and criminal penalties, in addition to other penalties of the Law.

DATED: New York, New York  
November 14, 2019

*Audrey Strauss*  
AUDREY STRAUSS  
Attorney for the United States Acting  
Under Authority Conferred by 28  
U.S.C. § 515

*RC*  
Richard Cooper/Daniel Tracer  
Assistant United States Attorneys  
One St. Andrew's Plaza  
New York, New York 10007  
Telephone: (212) 637-1027/2329



**RIDER**

**Takeda Pharmaceuticals U.S.A., Inc.**  
**c/o Chris Allen, Esq.**  
**One Takeda Parkway**  
**Deerfield, IL 60015**

Please produce the following:

1. Any and all records and communications relating to training sessions and information provided to the board of directors of Ariad Pharmaceuticals, Inc., relating to (a) confidentiality, (b) material, non-public information, and/or (c) insider training, for the period from 2013 through and including 2015; and
2. Any and all documents relating to certain entries contained on the chronology of events sent on June 11, 2014 to the United States Securities and Exchange Commission by counsel for Ariad Pharmaceuticals, Inc., which chronology is enclosed herewith for your reference. Please produce any and all documents for the entries on the following dates, all in 2013:
  - a. September 30
  - b. October 2
  - c. October 3
  - d. October 4
  - e. October 7
  - f. October 8
  - g. October 9
  - h. October 10
  - i. October 17
  - j. October 18
  - k. October 30
  - l. October 31
  - m. November 4
  - n. November 5
  - o. November 6
  - p. November 20
  - q. November 22
  - r. November 25
  - s. November 26
  - t. November 27
  - u. December 10
  - v. December 11
  - w. December 12
  - x. December 13
  - y. December 16
  - z. December 17
  - aa. December 18
  - bb. December 19
  - cc. December 20

Please forward the above requested information to AUSA Richard Cooper and SA Matthew Mahaffey at:

Richard.cooper@usdoj.gov and mdmahaffey@fbi.gov

or

United States Attorney  
Southern District of New York  
One Saint Andrews Plaza  
New York, NY 10007  
Attn: AUSA Richard Cooper

Federal Bureau of Investigation  
26 Federal Plaza  
New York, NY 10278  
Attn: SA Matthew Mahaffey - Squad C1

Please contact AUSA Richard Cooper at 212-637-1027 or SA Matthew Mahaffey at 212-384-2110 with any questions.

In lieu of hard copies, records are requested in digital format.

**IMPORTANT: REQUEST FOR NON-DISCLOSURE**

Due to the ongoing nature of the investigation, it is requested that you do not disclose any information relating to this grand jury subpoena request to any third party.

Declaration of Custodian of Records

Pursuant to 28 U.S.C. § 1746, I, the undersigned, hereby declare:

My name is \_\_\_\_\_.  
(name of declarant)

I am a United States citizen and I am over eighteen years of age. I am the custodian of records of the business named below, or I am otherwise qualified as a result of my position with the business named below to make this declaration.

I am in receipt of a Grand Jury Subpoena signed by Assistant United States Attorney Richard Cooper, requesting specified records of the business named below. Pursuant to Rules 902(11) and 803(6) of the Federal Rules of Evidence, I hereby certify that the records provided herewith and in response to the Subpoena:

- (1) were made at or near the time of the occurrence of the matters set forth in the records, by, or from information transmitted by, a person with knowledge of those matters;
- (2) were kept in the course of regularly conducted business activity; and
- (3) were made by the regularly conducted business activity as a regular practice.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on \_\_\_\_\_.  
(date)

\_\_\_\_\_  
(signature of declarant)

\_\_\_\_\_  
(name and title of declarant)

\_\_\_\_\_  
(name of business)

\_\_\_\_\_  
(business address)

Definitions of terms used above:

As defined in Fed. R. Evid. 803(6), "record" includes a memorandum, report, record, or data compilation, in any form, of acts, events, conditions, opinions, or diagnoses. The term "business" as used in Fed. R. Evid. 803(6) and the above declaration includes business, institution, association, profession, occupation, and calling of every kind, whether or not conducted for profit.

# MINTZ LEVIN

John F. Sylvia | 617 348 1820 | jsylvia@mintz.com

One Financial Center  
Boston, MA 02111  
617-542-6000  
617-542-2241 fax  
[www.mintz.com](http://www.mintz.com)

June 11, 2014

**CONFIDENTIAL TREATMENT REQUESTED**

By Hand

William J. Donahue  
Senior Enforcement Counsel  
United States Securities and Exchange Commission  
33 Arch Street, 23<sup>rd</sup> Floor  
Boston, MA 02110

RECEIVED

JUN 11 2014

SECURITIES AND EXCHANGE COMMISSION  
BOSTON REGIONAL OFFICE

Re: *In the Matter of Certain European-Based Parallel Trading Activity*  
SEC File No. B-02866


Dear Bill:

On behalf of ARIAD Pharmaceuticals, Inc. ("ARIAD"), I enclose a chronology of events preceding ARIAD's October 9, 2013 and December 20, 2013 Announcements. We have included reference to those individuals, of whom ARIAD is aware, that participated in significant interactions prior to the two Announcements. While the attached chronology does not reflect every single interaction that in any way related to the two Announcements, we believe the chronology captures the significant interactions prior to the Announcements. Per our prior discussions, I am hopeful that the chronology will assist in streamlining the additional requests in the SEC subpoena.

The enclosed material provided in response to the Commission's request constitutes ARIAD's proprietary business information. ARIAD therefore requests that the contents of this letter and the enclosed material be treated as confidential, non-public information pursuant to the Freedom of Information Act (5 U.S.C. § 552) as well as the confidentiality regulations applicable to the Commission set forth in 17 C.F.R. § 200.83. In the event that the Commission receives a request for disclosure of any of the materials or information contained herein, ARIAD requests that it be afforded notice and an opportunity to contest the disclosure in accordance with and pursuant to the applicable regulations. Any notification should be addressed to the attention of the undersigned.

Should you have questions regarding the foregoing information, please do not hesitate to contact me at (617) 348-1820. Thank you for your consideration.

Very truly yours,



John F. Sylvia

cc: Marc L. Mukasey, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

BOSTON | LONDON | LOS ANGELES | NEW YORK | SAN DIEGO | SAN FRANCISCO | STAMFORD | WASHINGTON

SEC-ARIAD-E-0000001

### Preliminary General Chronology

*In the Matter of Certain European-Based Parallel Trading Activity – SEC File No. B-02866*

The following table presents relevant correspondence between ARIAD, US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and various other parties regarding the discontinuation and resumption of commercial marketing of Iclusig® (ponatinib) covering the period of 27 September 2013 through 20 December 2013. Representatives from ARIAD, the FDA and the EMA that were known to be participant to the various communications are identified.

Date	Communication
27 September 2013	<ul style="list-style-type: none"> <li>• The FDA contacted ARIAD by telephone and requested that ARIAD representatives meet with the FDA in Silver Spring, MD on October 2. The FDA did not offer a specific agenda for the meeting. ARIAD requested that the FDA and ARIAD hold a call on Monday, September 30 to inform ARIAD of the intended agenda for the October 2 meeting. Immediately prior to the September 27 call, the FDA sent ARIAD an email regarding Iclusig safety matters related to safety datasets as part of the Prior Approval Supplement 005.           <ul style="list-style-type: none"> <li>○ <u>ARIAD</u> representative(s): Andrew Slugg.</li> <li>○ <u>FDA</u> representative(s): Lara Akinsanya.</li> </ul> </li> </ul>
28 September 2013	<ul style="list-style-type: none"> <li>• In an email, the FDA agreed to a September 30 call with ARIAD to clarify the purpose of the October 2 meeting.           <ul style="list-style-type: none"> <li>○ <u>ARIAD</u> representative(s): Andrew Slugg.</li> <li>○ <u>FDA</u> representative(s): Lara Akinsanya.</li> </ul> </li> </ul>

Date	Communication
30 September 2013	<ul style="list-style-type: none"> <li>On a conference call, the FDA explained that the purpose for the October 2 meeting was to exchange views regarding risk management in light of recent clinical safety data on Iclusig reviewed by the FDA.           <ul style="list-style-type: none"> <li><u>ARIAD representative(s)</u>: Dan Bollag, Andrew Slugg, Frank Haluska, Maureen Curran (former employee), Stephanie Lustgarten, and Ron Knickerbocker.</li> <li><u>FDA representative(s)</u>: Robert Kane, Angelo DeClaro, Nicole Verduin, Lara Akinsanya, Samantha Ryan.</li> </ul> </li> </ul>
2 October 2013	<ul style="list-style-type: none"> <li>At the meeting at the FDA White Oak Building in Silver Spring, MD, the FDA and ARIAD had a discussion about the ongoing safety events observed in the Iclusig clinical development program and postmarketing use, and requested that ARIAD present to the FDA an initial risk-management proposal.           <ul style="list-style-type: none"> <li><u>ARIAD representative(s)</u>: Tim Clackson, Frank Haluska, Dan Bollag, Andrew Slugg, Maureen Curran (former employee), and Kumiko Yanase.</li> <li><u>FDA representative(s)</u>: Robert Kane, Ann Farrell, Angelo DeClaro, Nicole Verduin, Julie Bullock, Stacey Ricci, Haleh Saber, Edwardas Kaminskas, Many others (22 in total) representing Office of Safety and Epidemiology (primarily) and other functions (project management, toxicology).</li> </ul> </li> </ul>

Date	Communication
3 October 2013	<ul style="list-style-type: none"> <li>• The FDA called ARIAD to discuss its proposed Drug Safety Communication.           <ul style="list-style-type: none"> <li>◦ <u>ARIAD representative(s)</u>: Frank Haluska, Andrew Slugg, Tim Clackson, Dan Bollag.</li> <li>◦ <u>FDA representative(s)</u>: Robert Kane, Ann Farrell, Angelo DeClaro, Nicole Verdun, and others.</li> </ul> </li> <li>• ARIAD's Executive Leadership Team<sup>1</sup> convened.</li> </ul>

<sup>1</sup> ARIAD's Executive Leadership Team consists of Harvey Berger, Tim Clackson, Ed Fitzgerald, Dan Bollag, Frank Haluska, David Bernstein, Maria Cantor and Marty Duvall. Pierre Dodion was also a member of the Executive Leadership Team. His employment terminated as of November 22, 2013. Most Executive Leadership Team members attend all meetings, but their attendance is not formally tracked.

Date	Communication
4 October 2013	<ul style="list-style-type: none"> <li>• At a pre-scheduled ARIAD-sponsored cardiovascular advisory board meeting (which started with dinner the evening before), participants were informed that ARIAD and the FDA were engaged in ongoing discussions about Iclusig safety data. Specific details regarding those discussions were not provided to any of the outside advisors. <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s):</u> Harvey Berger, Tim Clackson, Maureen Curran (former employee), Tawnee Felice (former employee), Frank Haluska, Ronald Knickerbocker, Jing Marantz (former employee), Tiffany Patrick, Victor Rivera, Andrew Slugg, Dan Bollag, Thomas Steele (former employee), Nikolaus Trede (former employee) Chris Turner, Kumiko Yanase.</li> <li>○ <u>Moderator:</u> Edward T.H. Yeh (The University of Texas M.D. Anderson Cancer Center).</li> <li>○ <u>Participants:</u> Ori Ben-Yehuda (Cardiovascular Research Foundation), Jorge Cortes (The University of Texas MD Anderson Cancer Center), David Moslehi (Brigham and Women's Hospital), Patrick Wen (Dana Farber Cancer Institute), Thomas Force (Temple University School of Medicine).</li> </ul> </li> <li>• The FDA called ARIAD and requested that written risk-management proposal be submitted by October 7.</li> <li>○ <u>ARIAD representative(s):</u> Andrew Slugg.</li> <li>○ <u>FDA representative(s):</u> Lara Akinsanya.</li> <li>• ARIAD's Executive Leadership Team convened.</li> <li>○ Jon Kravetz (Mintz Levin), Jeff Wiesen (Mintz Levin), Andrew Slugg, and Kendra Adams also attended the meeting.</li> <li>• Ed Fitzgerald sent a trading blackout email to ARIAD staff.</li> <li>• ARIAD's electronic Board of Directors portal was updated to indicate that the Board of Directors would discuss the evolving cardiovascular safety profile of Iclusig and recent FDA interactions on that topic at their upcoming meetings. The Board of Directors was apprised of the substance of the communications with the FDA at its October 7, 2013 telephonic meeting.<sup>4</sup></li> </ul>

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Date	Communication
5 October 2013	<ul style="list-style-type: none"> <li>Frank Haluska emailed Bruce Chabner, head of the EPIC (Clinical trial protocol AP24534-12-301) Data Monitoring Committee (DMC) to inform him of the ongoing discussions with the FDA and ARIAD's plans.</li> </ul>
7 October 2013	<ul style="list-style-type: none"> <li>ARIAD emailed to the FDA a written action plan that included a hold on new patient enrollment in ARIAD's clinical trials to the FDA, and requested a call with the FDA on October 8 to discuss. <ul style="list-style-type: none"> <li><u>ARIAD representative(s)</u>: Dan Bollag.</li> <li><u>FDA representative(s)</u>: Lara Akimanya.</li> </ul> </li> <li>ARIAD notified the EPIC DMC of its plan to temporarily hold enrollment of new patients in the EPIC trial. <ul style="list-style-type: none"> <li><u>EPIC DMC members</u>: Bruce Chabner, Michael Grossbard, Daniel Sargent, and John Goldman (UK)(deceased).</li> </ul> </li> <li>ARIAD's Board of Directors convened via conference call to discuss the recent communications with the FDA regarding the safety profile of Iclusig.</li> <li>ARIAD's Executive Leadership Team convened twice. <ul style="list-style-type: none"> <li>Jeff Wiesen (Mintz Levin) attended the first meeting.</li> </ul> </li> </ul>

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Date	Communication
8 October 2013	<ul style="list-style-type: none"> <li>• ARIAD participated in a conference call with the FDA to discuss ARIAD's plans. Specifically, ARIAD and the FDA discussed ARIAD's plans to place a hold on new patient enrollment in Iclusig clinical trials and to explore changes in dosing and other modifications to such clinical trials. After discussing these plans with ARIAD, the FDA indicated that it was placing a partial clinical hold on all new patient enrollment in Iclusig clinical trials. As requested by the FDA, ARIAD sent the FDA a list of all Iclusig clinical trials. <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s):</u> Dan Bollag, Frank Haluska, Tim Clackson and Andrew Slugg.</li> <li>○ <u>FDA representative(s):</u> Carolyn Yancey, Robert Kane, Angelo DeClaro, Ann Farrell, Nicole Verdun, Diane Lehman, Diane Hanner, Lara Akinsanya.</li> </ul> </li> <li>• ARIAD's Executive Leadership Team convened.</li> <li>• On October 8 and 9, ARIAD notified Health Authorities in regions with active clinical trials of Iclusig and ongoing marketing authorizations or applications (including the European Union, Switzerland, Canada, Australia, and Japan) about the temporary clinical hold and new instructions for Iclusig trials. Relevant members from ARIAD's contracted clinical research organizations (CROs), i.e., CMIC (Japan) and InVentiv Health, assisted ARIAD in this process. ARIAD sent "Dear Healthcare Provider" letters to physicians involved in Iclusig trials informing them of the partial clinical hold.</li> <li>• Frank Haluska called Hagop Kantarjian (MD Anderson) and Jorge Cortes (MD Anderson) to discuss the updated Iclusig safety data; Dr. Kantarjian subsequently informed Frank Haluska that he contacted Dan Longo (New England Journal of Medicine) the same day to inform him of the updated data.</li> </ul>

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83  
John F. Sylvia (617) 542-6000*

Date	Communication
8 October 2013	<ul style="list-style-type: none"> <li>ARIAD submitted to the European Medicines Agency (EMA) a notification of emerging safety information related to vascular occlusion events and proposed revisions to the prescribing information. In the letter, ARIAD requested a teleconference (TC) with the EMA, Rapporteur, and Co-Rapporteur and informed EMA of planned risk management activities by ARIAD and the intent of FDA to issue a Drug Safety Communication on this topic.           <ul style="list-style-type: none"> <li><u>ARIAD Representative(s)</u>: Thierry Bataillard, Tanja Fahlbusch, Sandra van der Pool-Smet (Deputy Qualified Person for Pharmacovigilance)</li> </ul> </li> </ul>
9 October 2013 (17:30 - 18:15, Tokyo)	<ul style="list-style-type: none"> <li>Representatives from ARIAD met with representatives from the PMDA (Pharmaceuticals and Medical Devices Agency) at a pre-planned meeting to discuss ARIAD's development strategy for ponatinib as a treatment for newly diagnosed CML. ARIAD used this opportunity to brief the PMDA on the developing regulatory events in the US, including the FDA's decision to place a partial-clinical hold on all new patient enrollments in clinical trials of ponatinib.</li> <li><u>ARIAD Representative(s)</u>: Andrew Slugg, Kumiko Yanase, Tim Clackson.</li> <li><u>ARIAD Consultant(s)</u>: Gregg Mayer, Hiroko Suzuki (translator), Atsushi Tanase (CMIC<sup>2</sup>), Hajimu Sakamoto (CMIC), Masakazu Takashima (CMIC).</li> <li><u>PMDA Representative(s)</u>: Toyotaka Iguchi: Review Director, Office of New Drug V; Daisuke Matsuda: Reviewer, Office of New Drug V.</li> </ul>

<sup>2</sup> CMIC is the in-country clinical caretaker (ICCC) for the ongoing phase ½ trial of ponatinib in Japan. CMIC is a Tokyo-based contract research organization hired by ARIAD.

Date	Communication
9 October 2013	<ul style="list-style-type: none"> <li>• ARIAD sent to the FDA a copy of its 9 October press release and the Dear Healthcare Provider letters that ARIAD had sent to Iclusig clinical investigators.           <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s)</u>: Dan Bollag.</li> <li>○ <u>FDA representative(s)</u>: Lara Akinsanya.</li> </ul> </li> <li>• ARIAD notified the PMDA (Japanese health authority) and CMIC of the updated safety data and partial US clinical hold. CMIC, as the sponsor of Iclusig trials in Japan, provided Dear Healthcare Provider letters to Iclusig investigators in Japan.</li> <li>• ARIAD issued a press release regarding the updated safety data and partial clinical hold. As indicated in the press release, ARIAD also held an open investor call at 8:30 AM on this date. See press release at: <a href="http://investor.riad.com">investor.riad.com</a></li> <li>• At a meeting of the Board of Directors, Board members were informed of and discussed Iclusig's evolving safety profile and recent FDA interactions.</li> </ul>
9 October 2013	<ul style="list-style-type: none"> <li>• ARIAD sent the EMA an email in follow-up to the 8 October 2013 letter providing an early copy of the Company's press release (before public release).           <ul style="list-style-type: none"> <li>○ <u>ARIAD Representative(s)</u>: Thierry Bataillard, Oulaya Belguenani.</li> <li>○ <u>EMA Representative(s)</u>: Elias Pean, Zahara Hanaizi.</li> </ul> </li> </ul>
10 October 2013	<ul style="list-style-type: none"> <li>• At a meeting of the Board of Directors, Board members continued their discussions regarding Iclusig's evolving safety profile and recent FDA interactions.</li> </ul>

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83  
 John F. Sylvia (617) 542-6000*

Date	Communication
11 October 2013	<ul style="list-style-type: none"> <li>The FDA published a Drug Safety Communication (DSC) regarding Iclusig: <a href="http://www.fda.gov/Drugs/DrugSafety/ucm370945.htm">http://www.fda.gov/Drugs/DrugSafety/ucm370945.htm</a>.</li> </ul>
On or before 14 October 2013	<ul style="list-style-type: none"> <li>ARIAD contacted United Biosource Corporation (UBC) regarding the development of a Risk Evaluation and Mitigation Strategy (REMS).           <ul style="list-style-type: none"> <li><u>ARIAD representative(s)</u>: Maureen Curran (former employee).</li> <li><u>UBC representative(s)</u>: Joe Devine.</li> </ul> </li> </ul>
14 October 2013	<ul style="list-style-type: none"> <li>ARIAD submitted Type II variation to the European Medicines Agency (EMA) to include new safety data in the Iclusig product information related to vascular occlusion, congestive heart failure, ocular toxicity, and neuropathy adverse reactions.</li> </ul>
17 October 2013	<ul style="list-style-type: none"> <li>ARIAD and FDA held a TC to discuss EPIC trial and agree to EPIC trial termination as well as other aspects of ongoing safety review.           <ul style="list-style-type: none"> <li><u>ARIAD representative(s)</u>: Dan Bollag, Andrew Slugg, Frank Haluska, Tim Cleckson.</li> <li><u>FDA representative(s)</u>: Richard Pazzdur, Ann Farrell, Robert Kane, Angelo DeClaro, Nicole Verdun, Diane Hanner, Lara Akinsanya, Kathleen Davis, Julie Bullock, Samantha Ryan, Cynthia LaCivita.</li> </ul> </li> </ul>
18 October 2013	<ul style="list-style-type: none"> <li>ARIAD Announces Discontinuation of the Phase 3 EPIC Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Investor conference call held at 8:30 AM. See press release at: <a href="http://investor.ariad.com">investor.ariad.com</a>.</li> </ul>

Date	Communication
24 October 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA held a TC to discuss the ongoing review of ARIAD New Drug Application (NDA) postmarketing Supplement 005<sup>3</sup>; specifically their comments on the datasets received from ARIAD, outstanding information requests, and next steps in the FDA review of the supplement.</li> <li>○ <u>ARIAD representative(s)</u>: Dan Bollag, Andrew Slugg, Frank Haluska, Tim Cleckson, Shirish Hirani, Marty Duvall, Maureen Curran (former employee), Ron Knickerbocker.</li> <li>○ <u>FDA representative(s)</u>: Richard Pazdur, Ann Farrell, Robert Kane, Angelo DeClaro, Nicole Verdun, Diane Hanner, Dianne Lehman, Lara Akinsanya, Kathleen Davis, Edwardas Kaminskas, Cynthia LaCivita, Julie Bullock.</li> </ul>

<sup>3</sup> This postmarketing supplement was a Prior Approval Supplement, as defined in 21 CFR 314.70(b), that was submitted by ARIAD on 31 August 2013 to NDA 203469 at the request of the FDA. “Supplement 005” was intended to affect changes to the warnings and precautions and adverse reactions sections of the US prescribing information for Iclusig.

Date	Communication
28 October 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA held a “working meeting” by TC and WebEx in the AM to discuss FDA’s review Supplement 005, primarily different methodologies that could be employed in evaluating dose intensity. ARIAD was asked by the FDA for a copy of its manuscript of the PACE trial planned for publication the New England Journal of Medicine (NEJM). Also, at the conclusion of the TC, the Iclusig Risk Management Plan (RMP) and the Summary of Medicinal Product Characteristics (SmPC) that had been submitted to the European Medicines Agency were requested by FDA. <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s)</u>: Dan Bollag, Andrew Slugg, Frank Haluska, Tim Clackson, Ron Knickerbocker, Shirish Hirani, Stephanie Lustgarten, Bao Le, Charles Deeck.</li> <li>○ <u>FDA representative(s)</u>: Angelo DeClaro, Nicole Verdun, Nicole Gormley, Lara Akinsanya, Diane V Leaman, Julie Bullock, Nitin Mehrotra, Jingyu Yu, Lei Nie, Kyung Lee.</li> </ul> </li> <li>• ARIAD and FDA held a second impromptu TC at FDA’s request to discuss the planned NEJM publication. The Office Director informed ARIAD of his position that the manuscript should be withdrawn by the authors even though it was accepted for publication by the Journal. The paper was published as planned on November 7, 2013. <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s)</u>: Daniel Bollag, Andrew Slugg, Frank Haluska, Tim Clackson, Ron Knickerbocker.</li> <li>○ <u>FDA Representative(s)</u>: Richard Pazdur, Ann Farrell, Edwardas Kaminskas, Robert Kane, Angelo DeClaro, Nicole Verdun, Jonathan Jarow, Diane Hamner, Diane Arrows, Lara Akinsanya.</li> </ul> </li> </ul>

11

Date	Communication
29 October 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA held a TC to discuss the ongoing review of Supplement 005 including the NEJM article, Iclusig marketing plan, and REMS.</li> <li>○ <u>ARIAD representative(s)</u>: Dan Bollag, Andrew Slugg, Frank Haluska, Tim Clackson, Ron Knickerbocker.</li> <li>○ <u>FDA representative(s)</u>: Richard Pazdur, Ann Farrell, Edvardas Kaminskas, Robert Kane, Angelo DeClaro, Nicole Verdun, Jonathan Jarow, Diane Hanner, Lara Akinsanya.</li> </ul>
30 October 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA held a TC to discuss the ARIAD NDA Marketing Plan and the potential voluntary suspension of marketing of Iclusig was discussed.</li> <li>○ <u>ARIAD representative(s)</u>: Dan Bollag, Andrew Slugg, Frank Haluska, Tim Clackson, Harvey Berger, Marty Duvall.</li> <li>○ <u>FDA representative(s)</u>: John Jenkins, Richard Pazdur, Ann Farrell, Edvardas Kaminskas, Robert Kane, Angelo DeClaro, Nicole Verdun, Diane Hanner, Lara Akinsanya.</li> </ul>

12

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Date	Communication
31 October 2013	<ul style="list-style-type: none"> <li>• ARIAD contacted the EMA by phone to inform them that the FDA has requested to temporarily suspend the commercialization of Iclusig in the USA. The EMA noted that on 29 October 2013 EMA had one of their regular teleconference calls with FDA and Iclusig was discussed. The FDA presented to EMA the different options they were considering but had not reached a conclusion at that time. Meeting participants were reported as being members of the Oncology Working Committee. ARIAD was informed that the Rapporteurs were informed of the meeting discussion. EMA noted that they were not aware of the final FDA position to request temporary suspension of the commercialization. On October 31, ARIAD informed EMA that this information would be made public on the FDA website today.</li> <li>• ARIAD was informed that another regular TC was planned between EMA and FDA this afternoon and Iclusig was on the agenda. ARIAD was informed that the purpose of the call was only an exchange of information and no decisions would be made. ARIAD was informed that as there is a confidentiality agreement between EMA and FDA, the EMA cannot share any information from the exchange with ARIAD until a final position has been reached. <ul style="list-style-type: none"> <li>○ <u>ARIAD Representative(s)</u>: Thierry Battaillard, Oulaya Belguenani, Jonathan Dickinson, Graham Moody.</li> <li>○ <u>EMA Representative(s)</u>: Elias Pean.</li> </ul> </li> </ul>
31 October 2013	<ul style="list-style-type: none"> <li>• ARIAD publicly announced the suspension of US sales and marketing of Iclusig: FDA issues Drug Safety Communication: <a href="http://www.fda.gov/Drugs/DrugSafety/ucm373040.htm">http://www.fda.gov/Drugs/DrugSafety/ucm373040.htm</a> Investor conference call held at 9:00 AM. See press release at: <a href="http://investor.ariad.com">investor.ariad.com</a>.</li> </ul>

13

Date	Communication
4 November 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA discussed establishment of an Emergency and Single Patient Investigational New Drug Application (eIND, sIND) processes to ensure continued access of patients who require treatment with Iclusig. FDA issued a Drug Safety Communication on 5 November 2013.           <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s)</u>: Dan Bollag, Andrew Slugg, Frank Haluska, Tim Clackson, Jing Marantz (former employee), Sean Daly, Shirish Hirani.</li> <li>○ <u>FDA representative(s)</u>: Richard Pazdur, Ann Farrell, Edvardas Kaminskas, Robert Kane, Angelo DeClaro, Nicole Verduin, Diane Hanner, Diane Lehman, Lara Akinsaruya, Cynthia LaCivita, Julie Bullock, Tammy Kim, David Joy, Stephanie Yao, and other FDA members.</li> </ul> </li> </ul>
5 November 2013	<ul style="list-style-type: none"> <li>• ARIAD was called by EMA and requested to attend the 6 November 2013 meeting of the EMA Pharmacovigilance and Risk Assessment Committee (PRAC) in their London office and was provided a list of questions regarding the ongoing Type II variation to address in advance of the meeting.           <ul style="list-style-type: none"> <li>○ <u>ARIAD Representative(s)</u>: Thierry Bataillard</li> <li>○ <u>EMA Representative(s)</u>: Elias Pean.</li> </ul> </li> </ul>
5 November 2013	<ul style="list-style-type: none"> <li>• FDA issued an update to the 31 October 2013 DSC on the suspension of marketing of Iclusig in the US, providing information to healthcare providers on how to continue those patients on the drug, and permit access to those new patients for whom all other available therapies have failed under an emergency investigational new drug (eIND) program. The information in this communication was also subsequently distributed to other stakeholders (e.g. members of the American Society of Clinical Oncology).</li> </ul>

14

**6 November 2013**

- ARIAD attended a meeting convened by PRAC at the EMA's office in London to discuss the ongoing Type II variation. The conclusion of the meeting was to, in the ongoing Type II variation, update the labeling and risk management plan (RMP) to include additional information on vascular occlusion and congestive heart failure with no revision to the indication. ARIAD was informed that other outstanding issues from the Type II variation would be considered in an Article 20 Referral procedure to begin in early-December 2013.

- **ARIAD representative(s):** Tim Clackson, Frank Haluska, Dan Bollag, Andrew Slugg, Shirish Hirani, Ron Knickerbocker, Maureen Curran (former employee), Christopher Turner, Thierry Bataillard, Oulaya Belguenani, Tanja Fahrbusch; Jonathan Dickinson.

- **EMA representative(s):** Elias Péan.

- **PRAC and CHMP representative(s)<sup>4</sup>:** Julia Dunne (UK), Rafe Suvanna (UK), Ulla Wändel Liminga (SE), Bertil Jonsson (SE).

- **PRAC Seating Chart:** Daniela Pomponiu (RO), Leonidas Kliromos (GR), Kamila Czajkowska (PL), Inguna Adovica (LV), Line Michan (DK), Alexandra Pego (PT), Kirsten Myhr (Expert), Fernanda Ferrazin (IT), Miguel Macia (ES), Menno van der Elst (NL), Evelyn Falip (FR), Nicolae Fotin (RO), Jacqueline Genoux-Hames (LU), George Aislaitner (GR), Gudrun Kristin Steingrimsdottir (IS), Lennart Waldenlind (Expert), Adam Przybykowski (PL), Andis Lacis (LV), Doris Stenver (DK), Margarida Guimaraes (PT), Filip Babylon (Expert), Carmela Macchiarulo (IT), Dolores Montero (ES), Yuliyan Efimov (BG), Kirsti Villikka (FI), Sabine Straus (NL), Isabelle Robine (FR), Brigitte Keller-Stanislawska (Expert), Milena Radhha-Bergoc (SI), Harald Herkner (AT), Julia Pallos (HU), Albert van der Zeijden (Expert), Maia Uuskula (EE), Tatjana Magalova (SK), Ingebjorg Buajordet (NO), Qun-Ying Yue (SE), Marieke De Bruin (Expert), Almath Spooner (IE), Martin Huber (DE), Eva Jirsova (CZ), Jean-Michel Dogné (BE), Viola Macolic Sarinic (HR), Julie Williams (UK), Jane Ahlqvist Rastad (Expert), Jolanta Gulbinovic (LT), Gabriela Jazbec (SI), Bettina Schade (AT), Katrin Kiisk (EE),

15

Date	Communication
	Anna Marekova (SK), Perrille Hang (NO), Ulka Wandel Liminga (SE), Ruchika Sharma (IE), Valerie Strassmann (DE), Veerle Verlinden (BE), Marin Banovac (HR), Julia Dunne (UK), Amy Tanti (MT), Herve Le Louet (Expert), June Raine (Chair), Peter Arlett (EMA) and Helen Lee (EC)
20 November 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA held a TC to discuss the ongoing review of NDA 203469, Supplement 005 and the potential path back to marketing for Iclusig.</li> <li>○ <u>ARIAD representative(s)</u>: Harvey Berger, Tim Clackson, Frank Haluska, Dan Bollag, Andrew Slugg, Shirish Hirani, Ron Knickerbocker, Maureen Curran (former employee).</li> <li>○ <u>FDA representative(s)</u>: Ann Farrell, Edvardas Kaminskas, Robert Kane, Angelo DeClaro, Nicole Verdun, Diane Hanner, Diane Lehman.</li> </ul>
22 November 2013	<ul style="list-style-type: none"> <li>• EMA issued “positive” opinion for Type II variation approving new labeling and RMP.</li> </ul>

<sup>4</sup> The Pharmacovigilance Risk Assessment Committee (PRAC) is the committee at the EMA that is responsible for assessing and monitoring safety issues for human medicines; the Committee for Medicinal Products for Human Use (CHMP) is the committee at the EMA that is responsible for preparing opinions on questions concerning medicines for human use. See, generally, [http://www.ema.europa.eu/ema/index.jsp?curl=pages/about\\_us/general/general\\_content\\_000217.jsp&mid=1000002](http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000217.jsp&mid=1000002).

The members and alternates of the PRAC are nominated by European Union Member States, in consultation with the Agency's Management Board, and include: a chair and a vice chair, elected by serving PRAC members; one member and an alternate nominated by each of the 28 Member States; one member and an alternate nominated by Iceland and by Norway; six independent scientific experts nominated by the European Commission; one member and an alternate nominated by the European Commission after consultation of the European Parliament to represent healthcare professionals; one member and one alternate nominated by the European Commission after consultation of the European Parliament to represent patients organizations. The EMA, PRAC, and CHMP committee members identified above are those who, to ARIAD's best recollection, were the most active participants in the direct discussions with ARIAD. The list titled PRAC Seating Chart is from a chart provided to ARIAD at the meeting of confirmed attendees. ARIAD did not verify the accuracy of the list. A full list of the current PRAC members is available at the EMA website: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/PRAC/people\\_listing\\_000112.jsp&mid=WC0b01ac058058f328](http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/PRAC/people_listing_000112.jsp&mid=WC0b01ac058058f328) and the list of current CHMP members is available at: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/2010/02/people\\_listing\\_000002.jsp&mid=WC0b01ac0580028c7c](http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/2010/02/people_listing_000002.jsp&mid=WC0b01ac0580028c7c).

Date	Communication
25 November 2013	<ul style="list-style-type: none"> <li>• ARIAD received a drug safety labeling change notification and REMS request letter from FDA.</li> </ul>
26 November 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA held a TC to discuss the safety labeling change notification and REMS request letter and response procedure.           <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s)</u>: Dan Bollag, Tim Clackson, Frank Haluska, Shirish Hirani, Andrew Slugg.</li> <li>○ <u>FDA representative(s)</u>: Ann Farrell, Edwardas Kaminskas, Robert Kane, Angelo DeClaro, Nicole Verdun, Diane Hanner, Diane Lehman.</li> </ul> </li> </ul>
27 November 2013	<ul style="list-style-type: none"> <li>• ARIAD submitted a prior-approval labeling supplement (NDA 203469, Supplement 007) to FDA with revised prescribing information in response to drug safety labeling change notification letter.</li> </ul>
29 November 2013	<ul style="list-style-type: none"> <li>• ARIAD received official notification of Article 20 referral procedure from EMA.</li> </ul>
3 December 2013	<ul style="list-style-type: none"> <li>• ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting. See press release at: investor.ariad.com.</li> </ul>
5 December 2013	<ul style="list-style-type: none"> <li>• ARIAD submitted a REMS supplement (NDA 203469, Supplement 008) to FDA in response to REMS request letter.</li> </ul>
On or before 10 December 2013	<ul style="list-style-type: none"> <li>• ARIAD contacted Havas Life regarding the development of the website and print materials for the Iclusig REMS.           <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s)</u>: Hamdan Almas (former employee).</li> <li>○ <u>UBC representative(s)</u>: Jay Hartmann.</li> </ul> </li> </ul>

17

Date	Communication
10 December 2013	<ul style="list-style-type: none"> <li>ARIAD contacted Berry PR—ARIAD's U.S. corporate public relations vendor—via telephone and email regarding anticipated Iclusig market resumption and logistics concerning expected timeframe for rolling out the announcement.           <ul style="list-style-type: none"> <li><u>ARIAD representative(s)</u>: Liza Heapes.</li> <li><u>Berry PR representative(s)</u>: Bill Berry, Andrea Coan.</li> </ul> </li> </ul>
~ 11 December 2013	<ul style="list-style-type: none"> <li>ARIAD contacted LehmenMillet—ARIAD's primary oncology marketing firm—via telephone to discuss logistics concerning updated Iclusig branded marketing materials in light of anticipated revised product information and resumption announcement.           <ul style="list-style-type: none"> <li><u>ARIAD representative(s)</u>: Tiffany Burt.</li> <li><u>LehmenMillet representative(s)</u>: Carrie Dandy, Kate Booth.</li> </ul> </li> </ul>
11 December 2013	<ul style="list-style-type: none"> <li>ARIAD contacted Biosector 2—ARIAD's European corporate public relations vendor of record—via telephone and email regarding anticipated Iclusig market resumption and logistics concerning expected timeframe for rolling out the announcement.           <ul style="list-style-type: none"> <li><u>ARIAD representative(s)</u>: Liza Heapes.</li> <li><u>Biosector 2 representative(s)</u>: Gemma White.</li> </ul> </li> </ul>

18

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Date	Communication
~ 11 December 2013	<ul style="list-style-type: none"> <li>• ARIAD contacted NASDAQ OMX via telephone concerning logistical standby preparations for hosting investor call and webcast in connection with an expected material announcement.</li> <li>○ <u>ARIAD representative(s)</u>: Kendra Adams.</li> <li>○ <u>NASDAQ OMX representative(s)</u>: Keir Walker.</li> </ul>
12 December 2013	<ul style="list-style-type: none"> <li>• ARIAD communicated with Berry PR via email and telephone regarding standby public relations preparations for anticipated Iclusig market resumption announcement.</li> <li>○ <u>ARIAD representative(s)</u>: Liza Heapes.</li> <li>○ <u>Berry PR representative(s)</u>: Bill Berry, Andrea Coan.</li> </ul>
12 December 2013	<ul style="list-style-type: none"> <li>• ARIAD submitted draft Important Safety Information to FDA Office of Prescription Drug Promotion (OPDP).</li> <li>○ <u>ARIAD representative(s)</u>: Andrew Slugg</li> <li>○ <u>FDA representative(s)</u>: Kathleen Davis</li> </ul>
12 & 13 December 2013	<ul style="list-style-type: none"> <li>• ARIAD communicated with HDM-ZooMedia via email and telephone regarding logistical website preparations for hosting anticipated market resumption announcement.</li> <li>○ <u>ARIAD representative(s)</u>: Liza Heapes.</li> <li>○ <u>HDM-ZooMedia representative(s)</u>: Christine Bennett, Dan Destrochers.</li> </ul>

19

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Date	Communication
13 December 2013	<ul style="list-style-type: none"> <li>• ARIAD submitted draft Core Promotional Material to FDA OPDP.           <ul style="list-style-type: none"> <li>○ <u>ARIAD</u> representative(s): Andrew Slugg.</li> <li>○ <u>FDA</u> representative(s): Kathleen Davis.</li> </ul> </li> </ul>
16 December 2013	<ul style="list-style-type: none"> <li>• ARIAD submitted Draft Core Promotional Material to FDA OPDP.           <ul style="list-style-type: none"> <li>○ <u>ARIAD</u> representative(s): Andrew Slugg.</li> <li>○ <u>FDA</u> representative(s): Kathleen Davis.</li> </ul> </li> </ul>
16 December 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA held a TC to finalize Post-Marketing Commitments related to approval of NDA 203469, Supplement 007.           <ul style="list-style-type: none"> <li>○ <u>ARIAD</u> representative(s): Dan Bollag, Tim Clackson, Ron Knickerbocker, Maureen Curran (former employee), Andrew Slugg.</li> <li>○ <u>FDA</u> representative(s): Ann Farrell, Edvardas Kaminskas, Qin Ryan, Angelo de Claro, Nicole Verdun, Diane Leaman, Theresa Carioti, Julie Bullock, Jingyu Yu, Lie Nie, Cynthia LaCivita, Kate Heinrich Ostell, Naomi Redd, Peter Waldron, Mwango Kashoki, Haley Seymour, Nancy Dickinson, Lindsay Davison, and Kathleen Davis.</li> </ul> </li> </ul>

20

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Date	Communication
16 December 2013	<ul style="list-style-type: none"> <li>• ARIAD communicated with Business Wire and Berry PR regarding draft press release announcing Iclusig market resumption.           <ul style="list-style-type: none"> <li>○ <u>ARIAD</u> representative(s): Liza Heapes.</li> <li>○ <u>Business Wire</u> representative(s): Michelle Gagne, Jen Saragosa, Tim Ragan.</li> <li>○ <u>Berry PR</u> representative(s): Bill Berry, Andrea Coan.</li> </ul> </li> </ul>
17 December 2013	<ul style="list-style-type: none"> <li>• ARIAD submitted the Final REMS to Supplement 008.</li> </ul>
17 December 2013	<ul style="list-style-type: none"> <li>• ARIAD communicated with HDM-ZooMedia via email and telephone regarding changes to implementation in “DEV site” (pre-live website) in preparation for going live with market resumption announcement           <ul style="list-style-type: none"> <li>○ <u>ARIAD</u> representative(s): Liza Heapes.</li> <li>○ <u>ZooMedia</u> representative(s): Christine Bennett, Dan Desrochers.</li> </ul> </li> </ul>
18 December 2013	<ul style="list-style-type: none"> <li>• ARIAD submitted the Iclusig Launch Plan to Supplement 007.</li> </ul>

21

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Date	Communication
18 December 2013	<ul style="list-style-type: none"> <li>• Pursuant to an embargoed-media release, ARIAD circulated market resumption press release to, and conducted phone interview with, media contacts at Boston Globe, Bloomberg News, Wall Street Journal and New York Times.           <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s)</u>: Harvey Berger, Liza Heapes.</li> <li>○ <u>Boston Globe representative(s)</u>: Rob Weisman.</li> <li>○ <u>Bloomberg News representative(s)</u>: Meg Tirrell.</li> <li>○ <u>Wall Street Journal representative(s)</u>: Joseph Walker; Ron Winslow (no interview).</li> <li>○ <u>New York Times representative (s)</u>: Andy Pollack, Denise Grady (Denise Grady was part of embargoed-outreach but interview was with Andy Pollack).</li> </ul> </li> </ul>
18 December 2013	<ul style="list-style-type: none"> <li>• ARIAD submitted the Final USPI, Medication Guide and Final Post Marketing Requirements (PMRs) to supplement 007.</li> </ul>
19 December 2013	<ul style="list-style-type: none"> <li>• ARIAD and FDA held TC regarding next steps in labeling and REMS supplements. FDA mentions possible FDA action on supplements 007 and 008 on 20 December 2013.           <ul style="list-style-type: none"> <li>○ <u>ARIAD representative(s)</u>: Andrew Slugg.</li> <li>○ <u>FDA representative(s)</u>: Theresa Carioti.</li> </ul> </li> </ul>

22

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Date	Communication
19 December 2013	<ul style="list-style-type: none"> <li>• ARIAD communicated with HDM-ZooMedia on coordinating final changes to implement in the DEV (pre-live) site in preparation for going live with market resumption announcement.</li> <li>○ <u>ARIAD representative(s)</u>: Tom Malone.</li> <li>○ <u>HDM-ZooMedia representative(s)</u>: Christine Bennett.</li> </ul>
20 December 2013	<ul style="list-style-type: none"> <li>• FDA approved Supplement 007 and 008 for revised prescribing information and REMS for Iclusig.</li> </ul>
20 December 2013	<ul style="list-style-type: none"> <li>• ARIAD Announces U.S. Resumption of Marketing and Commercial Distribution of Iclusig (ponatinib) in Refractory Philadelphia-Positive Leukemias. Investor call held at 11:30 AM. See press release at: investor.ariad.com.</li> </ul>

23

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

## Appendix I

Relevant ARIAD Employees

Last Name	First Name	Title (as of applicable time period: ~ September 2013 - December 2013)
Executive Leadership Team (ELT)		
Berger	Harvey	Chairman and Chief Executive Officer
Berstein	David	Senior Vice President, Chief Intellectual Property Officer and General Counsel
Bollag	Daniel	Senior Vice President, Regulatory Affairs
Cantor	Maria	Senior Vice President, Corporate Affairs
Clackson	Timothy	President of R&D and Chief Scientific Officer
Dodion	Pierre	Senior Vice President (former employee)
Duvall	Martin	Senior Vice President, Commercial Operations
Fitzgerald	Edward	Executive Vice President, Chief Financial Officer and Treasurer
Haluska	Frank	Chief Medical Officer and Senior Vice President

24

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

<b>Senior Management</b>		
Chan	Kai	Head of Medical Affairs Europe
Dickinson	Jonathan	General Manager, EU
Falbusch	Tanja	Head of Pharmacovigilance Europe
Hirani	Shrirish	Vice President, Program and Alliance Management
Knickerbocker	Ron	Vice President, Biomedical Data Sciences and Information
Marantz	Jing	Vice President, Medical Affairs (former employee)
Rivera	Victor	Vice President, Preclinical and Translational Research
<b>Senior Directors</b>		
Bataillard	Thierry	EU Regulatory Lead
Curran	Maureen	Senior Director, Pharmacovigilance (former employee)
Daly	Sean	Senior Director, Clinical Operations
Deeck	Charles	Senior Director, Regulatory Operations
Patrick	Tiffany	Senior Director, Outreach Medical Education & Advocacy

25

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

Slugg	Andrew	Senior Director, Regulatory Affairs
Yanase	Kumiko	Senior Medical, Director
Zhang	Josh	Senior Medical Director (former employee)
<b>Directors</b>		
Adams	Kendra	Director, Investor Relations
du Moulin	Ruth	Director Medical and Scientific Communications
Lustgarten	Stefanie	Director, Biostatistics and Statistical
Steele	Thomas	Director, Preclinical Safety (former employee)
Trede	Nikolaus	Medical Director (former employee)
<b>Associate Directors</b>		
Belguenani	Oulaya	Associate Director, Regulatory Affairs Europe
Burt	Tiffany	Associate Director, Oncology Marketing
Malone	Tom	Associate Director, Internal Communications
Moody	Graham	Associate Director, Regulatory Operations EU

26

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83  
John F. Sylvia (617) 542-6000*

<b>Managers</b>		
Almas	Hamdan	Senior Product Manager, Oncology Marketing (former employee)
Felice	Tawnee	Manager, Outreach Med. Education & Adv. (former employee)
Heapes	Liza	Senior Manager Corporate Communications
Le	Bao	Manager, Regulatory Affairs
Wetherill	Yelena	Clinical Research Scientist (former employee)

**FDA Employees:**

The investigational new drug application (IND) and new drug application (NDA) for Iclusig® (ponatinib) for the treatment of CML and Ph+ ALL are held under the Division of Hematology Products (DHP) in the Office of Hematology and Oncology Products (OHOP) within the Center for Drug Evaluation and Research (CDER). The following list includes individuals from the DHP, OHOP and CDER who were, to the best of ARIAD's knowledge, involved in the review of the Iclusig IND and NDA during the period in question.

To the best of ARIAD's knowledge, the medical reviewers from the DHP for these applications for the period were Nicole Verdun and Angelo De Claro acting with Robert Kane (Deputy Director, Safety) under the supervision of the Division Director Ann Farrell who reports to Richard Pazzdur, Director of the Office of Hematology and Oncology Products.

**Center for Drug Evaluation & Research (CDER)**

Janet Woodcock, M.D., Director, Center for Drug Evaluation & Research

**Office of New Drugs, Immediate Office (OND)**

John Jenkins, M.D., Director, Office of New Drugs

Mwango Kashoki, MD, Associate Director for Safety

**Office of Hematology and Oncology Products (OHOP)**

Richard Pazzdur, M.D., Office Director

Jonathan Jarrow, M.D., Acting Associate Office Director

Tamy Kim, Pharm.D., Associate Director for Regulatory Affairs

**Division of Hematology Products (DHP)**

Ann T. Farrell, M.D., Division Director

Edwardas Karimskas, M.D., Deputy Division Director

Robert Kane, M.D., Deputy Director, safety

Qin Ryan, MD, PhD, Medical Officer for Safety

Angelo DeClaro, M.D., Acting Clinical Team Leader

Albert Deisseroth, M.D., Ph.D., Medical Officer

28

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83  
John F. Sylvia (617) 542-6000*

Nicole Verdun, M.D., Medical Officer

Lara Akinsanya, M.S., Senior Regulatory Health Project Manager

Diane Hanner, Senior Program Management Officer

Theresa Carioti, MPH, Regulatory Project Manager

Nicole Gormley, Clinical Team

Diane V Leaman, Safety Regulatory Health Project Manager

**Office of Surveillance and Epidemiology/ Division of Risk Management (DRISK)**

Cynthia LaCivita, PharmD, Team Leader

Carolyn Yancey, M.D., Medical Officer

Kate Heinrich Osswell, PharmD, Drug Risk Management Analyst

Naomi Redd, PharmD, Drug Risk Management Analyst

**Office of Surveillance and Epidemiology/ Division of Pharmacovigilance 2**

Peter Waldron, MD, Medical Officer

**Office of Compliance**

Haley Seymour, MS, Consumer Safety Officer

**Office of Regulatory Policy**

Nancy Dickinson, PharmD

29

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*

*John F. Sylvia (617) 542-6000*

**Division of Regulatory Policy 1 (DRP1)**

David Joy, Senior Regulatory Counsel

**Office of Clinical Pharmacology (OCP)**

Julie Bullock, PharmD, Clinical Pharmacology Team Leader

Nitin Mehrotra, Division of Pharmacometrics Team Leader

Jingyu Yu, Pharmacometrics Reviewer

**Office of Biostatistics, Division of Biometrics V (DBV)**

Lei Nie, Ph.D., Statistical Team Leader

Kyung Lee, Ph.D., Statistician

**Division of Hematology and Oncology Toxicology (DHOT)**

Haleh Saber, Ph.D., Toxicology Team Leader

Stacey Ricci, M.Eng. Sc.D., Toxicology Reviewer

**Office of Prescription Drug Promotion (OPDP)**

Katie Davis, RN, Regulatory Review Officer

**Office of Media Affairs**

Stephanie Yao, Press Officer

**FDA's Office of Communications**

30

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*

*John F. Sylvia (617) 542-6000*

Lindsay Davison, PharmD, Health Promotion Officer

31

*Confidential Treatment Requested Pursuant to 17 C.F.R. § 200.83*  
*John F. Sylvia (617) 542-6000*

# Exhibit 2

Ropes & Gray LLP

**Ropes & Gray Fees**

Work Date	Name	Title	Agreed Rate	Narrative/ Cost Description	Billed Hours	Billed Amount
11/25/2019	Welsh, Peter L.	PARTNER	1,075.00	Read chronology and subpoena, emails with D. O'Connor, A. Hancock and client.	1.5	1,612.50
11/26/2019	Welsh, Peter L.	PARTNER	1,075.00	Emails with client and team concerning subpoena and subpoena compliance.	0.3	322.50
11/26/2019	Hancock, Anne F.	ASSOCIATE	770.00	Coordinate document collection efforts.	0.3	231.00
11/26/2019	Hancock, Anne F.	ASSOCIATE	770.00	Analyze board meeting materials and documents received regarding SEC chronology and draft email regarding same for DOJ request.	1.5	1,155.00
11/26/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Coordinate with Takeda E-Discovery team to transfer collected files for review, and discuss content of same with A. Hancock.	1	425.00
11/26/2019	Rose, Aaron B.	LIT SUPP ANALST	370.00	Create Relativity database in preparation for document review.	0.2	74.00
11/26/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Prepare documents for processing in internal review platform.	0.5	160.00
11/27/2019	Welsh, Peter L.	PARTNER	1,075.00	Emails with client, D. O'Connor, A. Hancock concerning insider trading subpoena.	0.3	322.50
11/27/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Review request from government and discuss same with A Hancock and discuss same with client, discuss historical productions with counsel at Mintz for DOJ request.	1.8	1,935.00
11/27/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with J. Sylvia to discuss SEC inquiry.	0.5	385.00
11/27/2019	Hancock, Anne F.	ASSOCIATE	770.00	Analyze DOJ subpoena and underlying DOJ indictment.	1	770.00
11/27/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with M. Nevin to discuss case background and production plan.	0.5	385.00
11/27/2019	Hancock, Anne F.	ASSOCIATE	770.00	Revise list of relevant individuals referenced in SEC chronology for litigation hold purposes for DOJ request.	0.4	308.00
11/27/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with P. Welsh regarding restitution of fees.	0.3	231.00
11/27/2019	Hancock, Anne F.	ASSOCIATE	770.00	Develop work plan for document collection and review.	0.8	616.00
11/27/2019	McDonald, Katherine	ASSOCIATE	550.00	Onboarding call with A. Hancock.	0.3	165.00
11/27/2019	McDonald, Katherine	ASSOCIATE	550.00	Review Board of Directors documents for material responsive to DOJ subpoena.	2.8	1,540.00
11/27/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft spreadsheet of Ariad employees referenced in SEC chronology for litigation hold for DOJ request.	0.5	275.00
11/27/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussions with A. Hancock and C. Evans regarding importing of client-collected data and preparations for searching and review by associate team.	1	425.00
11/27/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Per A. Hancock and K. McDonald, prepare search results set from collected Board of Directors minutes for review in document review platform.	0.7	297.50
11/27/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Prepare Gibson Dunn and Mintz Levin Productions for processing with C. Evans and A. Hancock.	1	425.00
11/27/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Perform quality control checks on processed data set in internal review platform.	0.7	224.00
11/27/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Process dataset in internal review platform.	1.5	480.00
11/28/2019	McDonald, Katherine	ASSOCIATE	550.00	Continue reviewing Board of Directors documents for material responsive to DOJ subpoena.	2.5	1,375.00
11/29/2019	Hancock, Anne F.	ASSOCIATE	770.00	Draft work plan for document review and production.	0.2	154.00
11/29/2019	McDonald, Katherine	ASSOCIATE	550.00	Review documents for materials responsive to DOJ subpoena and draft summary regarding same.	4.3	2,365.00
11/29/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review and respond to emails from C. Evans regarding preparing metadata fields within production load files received from Mintz KLevin and Gibson Dunn.	0.5	212.50
11/29/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Prepare client production data set for ingestion into internal review platform	1.3	416.00
11/30/2019	McDonald, Katherine	ASSOCIATE	550.00	Assemble proposed documents for production.	2.3	1,265.00
11/30/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft summary of review of Board of Directors materials for upcoming production.	2.8	1,540.00
12/1/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review proposed production set and comment regarding same.	1.4	1,078.00
12/1/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft summary of review of Board of Directors materials for DOJ production.	1.1	605.00
12/1/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discuss import of Mintz Levin and Gibson Dunn production volumes with K. McDonald, A. Hancock and C. Evans.	0.4	170.00
12/1/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Process production data set into internal review platform for case team review.	1	320.00
12/2/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Review materials for production and discuss same with A Hancock	0.3	322.50
12/2/2019	Hancock, Anne F.	ASSOCIATE	770.00	Email with J. Sylvia regarding prior productions for DOJ production.	0.2	154.00
12/2/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review production and update regarding confidentiality provisions.	0.7	539.00
12/2/2019	Hancock, Anne F.	ASSOCIATE	770.00	Meet with D. O'Connor to discuss proposed productions and make edits in light of same.	0.9	693.00
12/2/2019	Hancock, Anne F.	ASSOCIATE	770.00	Email with M. Nevin.	0.4	308.00
12/2/2019	McDonald, Katherine	ASSOCIATE	550.00	Review documents previously produced by ARIAD's prior counsel for production to AUSA's current request.	1.5	825.00

**Ropes & Gray Fees**

Work Date	Name	Title	Agreed Rate	Narrative/ Cost Description	Billed Hours	Billed Amount
12/2/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft litigation hold notice for Takeda based on DOJ request.	1	550.00
12/2/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussions with C. Evans regarding completion of processing Mintz Levin and Gibson Dunn production volumes to internal document review platform to respond to DOJ request.	0.4	170.00
12/2/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Per A. Hancock circulate board materials to M. Nevin for review for DOJ request.	0.4	170.00
12/2/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discuss redacting documents in document review platform with A. Hancock and K. McDonald.	0.3	127.50
12/2/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Perform quality control measures on ingested data set in internal review platform.	0.5	160.00
12/2/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Process production data set in internal review platform for case team review.	1.5	480.00
12/3/2019	Welsh, Peter L.	PARTNER	1,075.00	Conference with D. O'Connor and A. Hancock, telephone conference with client regarding response to DOJ request.	0.5	537.50
12/3/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Review litigation hold, exchange emails with team regarding email from DOJ and plan to respond to DOJ requests and conduct call with DOJ on same.	0.8	860.00
12/3/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Prep for and conduct call with client (M Nevin).	0.8	860.00
12/3/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with the DOJ to discuss subpoena.	0.3	231.00
12/3/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with M. Nevin.	0.5	385.00
12/3/2019	Hancock, Anne F.	ASSOCIATE	770.00	Draft spreadsheet regarding key custodians for e-discovery collection efforts for DOJ response.	1.6	1,232.00
12/3/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with P. Welsh to discuss case status.	0.2	154.00
12/3/2019	Hancock, Anne F.	ASSOCIATE	770.00	Email regarding production logistics and DOJ requirements.	0.5	385.00
12/3/2019	Hancock, Anne F.	ASSOCIATE	770.00	Email regarding potential privilege issues and review proposed redactions to board materials.	1.4	1,078.00
12/3/2019	McDonald, Katherine	ASSOCIATE	550.00	Redact privileged material for upcoming production to DOJ.	2.3	1,265.00
12/3/2019	McDonald, Katherine	ASSOCIATE	550.00	Revise draft litigation hold notice for Takeda for DOJ request.	0.3	165.00
12/3/2019	McDonald, Katherine	ASSOCIATE	550.00	Create annotated spreadsheet of SEC chronology for DOJ production.	1.4	770.00
12/3/2019	McDonald, Katherine	ASSOCIATE	550.00	Call with client to discuss upcoming production to DOJ.	0.2	110.00
12/3/2019	Eagon, Haley	ASSOCIATE	485.00	Review relevant board materials for privilege and apply necessary redactions. Prepare materials for production.	3.7	1,794.50
12/3/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Per A. Hancock, export iterations of proposed redactions on board materials and circulate sets to M. Nevin for review.	1.3	552.50
12/3/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Conference call with S. Meyers, D. O'Connor and A. Hancock regarding scope of discovery for DOJ request.	0.3	127.50
12/3/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Coordinate with C. Evans to import additional documents into review platform and prepare set for draft production.	0.4	170.00
12/3/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Assist K. McDonald with applying redactions to board materials.	0.2	85.00
12/3/2019	Moree, Kristina D.	LIT SUPP ANALST	370.00	Update database security to grant reviewer access.	0.1	37.00
12/3/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Prepare documents in internal review platform in preparation for productions.	1	320.00
12/3/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Process data set in internal review platform in preparation of production.	0.5	160.00
12/4/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review and revise potential privilege concerns with respect to board materials for DOJ request.	3.1	2,387.00
12/4/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with D. O'Connor to discuss production and privilege concerns.	0.4	308.00
12/4/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with M. Nevin to discuss collection and custodian review.	0.5	385.00
12/4/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review board materials and excerpt responsive materials.	2.9	2,233.00
12/4/2019	Hancock, Anne F.	ASSOCIATE	770.00	Finalize production letter with edits from D. O'Connor.	0.6	462.00
12/4/2019	Hancock, Anne F.	ASSOCIATE	770.00	Finalize production and submit same to the DOJ.	0.6	462.00
12/4/2019	McDonald, Katherine	ASSOCIATE	550.00	Call with client to discuss upcoming document production.	0.3	165.00
12/4/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft cover letter to document production in response to November 14, 2019 subpoena.	0.3	165.00
12/4/2019	McDonald, Katherine	ASSOCIATE	550.00	Prepare documents for production to DOJ in response to November 14, 2019 subpoena.	3.6	1,980.00
12/4/2019	Eagon, Haley	ASSOCIATE	485.00	Finalize board materials for production.	1.3	630.50
12/4/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Prepare, finalize and circulate document production of board materials to DOJ.	3	1,275.00
12/4/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussions with A. Hancock and K. McDonald.	0.5	212.50
12/4/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Prepare and circulate updated versions of proposed board book materials for production.	1	425.00
12/4/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist the case team in preparing dataset in internal review platform in preparation for production.	1.3	416.00
12/4/2019	Dobkins, Allyssa	PARALEGAL	235.00	Assist A. Hancock with outgoing production materials.	1.8	423.00
12/5/2019	Hancock, Anne F.	ASSOCIATE	770.00	Revise search terms and priority custodian list based on SEC chronology.	1.1	847.00

**Ropes & Gray Fees**

Work Date	Name	Title	Agreed Rate	Narrative/ Cost Description	Billed Hours	Billed Amount
12/5/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft search terms for client document collection.	1.8	990.00
12/5/2019	McDonald, Katherine	ASSOCIATE	550.00	Create spreadsheet of ARIAD custodians ranked by priority.	1.1	605.00
12/5/2019	Eagon, Haley	ASSOCIATE	485.00	Confer with K. McDonald, draft and finalize proposed search terms for client email review.	2.1	1,018.50
12/5/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review emails with S. Meyers regarding scope of custodial email collection	0.2	85.00
12/5/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Coordinate with Mintz Levin regarding electronic transfer of production data.	0.3	127.50
12/6/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review prior production letters for potentially responsive material and email with J. Sylvia regarding same.	0.7	539.00
12/6/2019	McDonald, Katherine	ASSOCIATE	550.00	Review files produced to the SEC by ARIAD's prior counsel for materials for DOJ.	1.5	825.00
12/6/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft summary of Takeda's corporate transactions history for corporate witness issue.	1.3	715.00
12/6/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft summary of indictment in United States v. Nikas to further response to DOJ requests.	1	550.00
12/6/2019	McDonald, Katherine	ASSOCIATE	550.00	Review case files in United States v. Nikas docket.	0.3	165.00
12/6/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft chronology of Iclusig trials and marketing and distribution timeline as part of responding to DOJ requests.	2	1,100.00
12/6/2019	Eagon, Haley	ASSOCIATE	485.00	Draft historical summary of Takeda's major transactions related to witness question.	2.1	1,018.50
12/6/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussion with K. McDonald regarding native file content of Mintz Levin production, and circulate summary to A. Hancock.	0.5	212.50
12/6/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Coordinate transfer of production data with Mintz Levin for response to DOJ questions.	0.4	170.00
12/6/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Coordinate with C. Evans to download and extract Mintz Levin production volumes.	0.3	127.50
12/6/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Download and extract Gibson Dunn production volume for DOJ response, and discuss content with K. McDonald.	0.3	127.50
12/6/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussions with S. Meyers and A. Hancock regarding collection volumes of custodial email data.	0.4	170.00
12/8/2019	Hancock, Anne F.	ASSOCIATE	770.00	Draft email regarding corporate transactions history for D. O'Connor.	0.6	462.00
12/8/2019	Hancock, Anne F.	ASSOCIATE	770.00	Revise summary of case history for D. O'Connor.	0.2	154.00
12/8/2019	Hancock, Anne F.	ASSOCIATE	770.00	Revise summary of DOJ indictment for D. O'Connor.	0.7	539.00
12/8/2019	McDonald, Katherine	ASSOCIATE	550.00	Revise summary of indictment in United States v. Nikas.	0.4	220.00
12/8/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review and discuss plan for production of native files with A. Hancock, K. McDonald and C. Evans.	0.5	212.50
12/9/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Email client summary of conversation with DOJ related to privilege log and discuss same with team	0.3	322.50
12/9/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review proposed production to the DOJ and email regarding same.	0.9	693.00
12/9/2019	Hancock, Anne F.	ASSOCIATE	770.00	Revise production letter to the DOJ.	0.3	231.00
12/9/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft cover letter for upcoming document production.	0.4	220.00
12/9/2019	McDonald, Katherine	ASSOCIATE	550.00	Review productions for material to DOJ supportive of SEC chronology entries.	2.1	1,155.00
12/9/2019	Eagon, Haley	ASSOCIATE	485.00	Review previous productions to Government and summarize relevant ARIAD/FDA communications.	2.4	1,164.00
12/9/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Coordinate with C. Evans on import of Ariad production volume received from Mintz Levin.	0.2	85.00
12/9/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussions with A. Hancock and K. McDonald regarding production of native files	0.4	170.00
12/9/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Communications with S. Meyers regarding users to DISCO hosted review platform.	0.4	170.00
12/9/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Export supplemental native file production from original Mintz Levin production volume, and cross-check native files against previously produced version.	0.7	297.50
12/9/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Process client production data set into internal review platform.	0.7	224.00
12/9/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Perform quality control measures on ingested data sets.	0.3	96.00
12/9/2019	Harry, Saron	PARALEGAL	310.00	Access Disco and communications with G. Malek regarding database.	0.1	31.00
12/10/2019	Hancock, Anne F.	ASSOCIATE	770.00	Draft production letter and finalize production of materials to the DOJ.	1.3	1,001.00
12/10/2019	McDonald, Katherine	ASSOCIATE	550.00	Assemble proposed production for client review.	0.3	165.00
12/10/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussion with associate team regarding preparations for document production.	0.3	127.50
12/10/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussion with K. McDonald regarding approach to running search terms on custodial email population.	0.3	127.50

**Ropes & Gray Fees**

Work Date	Name	Title	Agreed Rate	Narrative/ Cost Description	Billed Hours	Billed Amount
12/10/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review and discuss processing of data into DISCO review platform with S. Meyers.	0.4	170.00
12/10/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Provide summary of custodial data totals to associate team.	0.2	85.00
12/10/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team with preparing document set for production.	0.3	96.00
12/10/2019	Harry, Saron	PARALEGAL	310.00	Review team email regarding production. Communications with D. Albert-Rozenberg regarding service of production.	0.2	62.00
12/10/2019	Albert-Rozenberg, Daniel	PARALEGAL	235.00	Serve production for A Hancock.	0.5	117.50
12/11/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Communicate with team on new requests and discuss same J Slivia at Mintz	0.8	860.00
12/11/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with J. Sylvia to discuss DOJ request for redacted emails.	0.2	154.00
12/11/2019	Hancock, Anne F.	ASSOCIATE	770.00	Correspondence with D. O'Connor regarding document collection and production.	0.3	231.00
12/11/2019	Hancock, Anne F.	ASSOCIATE	770.00	Analyze search term results and email regarding document review logistics.	0.4	308.00
12/11/2019	McDonald, Katherine	ASSOCIATE	550.00	Communicate with client.	0.3	165.00
12/11/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Attend overview of client's e-discovery platform provided by CSDISCO.	1	425.00
12/11/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Per A. Hancock prepare search term and custodian reports for analysis.	1.2	510.00
12/11/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review and circulate additional Mintz files for importing into review platform and redacting prior to production.	0.2	85.00
12/11/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Communicate with client's data hosting vendor to discuss work flow for using external review platform.	1	320.00
12/11/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team by generating metrics to assist in their review of client data set.	0.5	160.00
12/11/2019	Harry, Saron	PARALEGAL	310.00	Compile and import into FileSite production letters.	0.1	31.00
12/12/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review documents withheld for privilege and draft email to D. O'Connor summarizing same.	0.7	539.00
12/12/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with G. Malek to discuss search criteria and results.	0.3	231.00
12/12/2019	McDonald, Katherine	ASSOCIATE	550.00	Call with associate team to discuss email collection and review.	0.2	110.00
12/12/2019	McDonald, Katherine	ASSOCIATE	550.00	Correspond with client regarding upcoming production.	0.5	275.00
12/12/2019	McDonald, Katherine	ASSOCIATE	550.00	Redact privileged material for upcoming production.	1.2	660.00
12/12/2019	Eagon, Haley	ASSOCIATE	485.00	Apply redactions to various BOD communications for production on 12/16.	1.4	679.00
12/12/2019	Eagon, Haley	ASSOCIATE	485.00	Draft and review relevant search terms for document collection, and confer with R&G team regarding the same.	1.2	582.00
12/12/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Coordinate with C. Evans to prepare updated search term and custodian hit report.	0.3	127.50
12/12/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Coordinate with C. Evans to import documents received from Mintz Levin into review platform for redaction, and circulate draft copies to M. Nevin for review.	0.6	255.00
12/12/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Call with A. Hancock, H. Eagon, and K. McDonald regarding search term results.	0.3	127.50
12/12/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Communicate with case team regarding work flow for reviewing data set in client's review platform.	0.3	96.00
12/12/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Prepare documents for processing in internal review platform.	0.2	64.00
12/12/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team with preparing documents for review by client in preparation of production.	0.3	96.00
12/12/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team by generating metrics from external review platform to assist in review.	0.3	96.00
12/12/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Process dataset in internal review platform to assist case team in review.	0.3	96.00
12/13/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review and revise searches in response to DOJ subpoena.	0.3	231.00
12/13/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with D. O'Connor to discuss document review and production of documents referenced in the privilege log per DOJ request.	0.2	154.00
12/13/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review proposed redactions to documents referenced on the privilege log requested by the DOJ.	0.3	231.00
12/13/2019	Eagon, Haley	ASSOCIATE	485.00	Update draft letter for 12/16 document production.	0.5	242.50
12/13/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review and discuss updated custodian and search term parameters against email collection with A. Hancock and C. Evans.	0.3	127.50
12/13/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team by generating metrics to assist in their review of client data set.	2.3	736.00
12/15/2019	Eagon, Haley	ASSOCIATE	485.00	Review database search results and update master spreadsheet regarding the same for DOJ production.	0.7	339.50
12/15/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review and discuss search term and custodian reporting and results with C. Evans.	0.4	170.00
12/15/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team by generating metrics to assist in their review of client data set.	2	640.00

**Ropes & Gray Fees**

Work Date	Name	Title	Agreed Rate	Narrative/ Cost Description	Billed Hours	Billed Amount
12/16/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Discuss conversation with DOJ about limiting review path and request on privilege log review with client and team, call with DOJ on same.	1.3	1,397.50
12/16/2019	Harrison, Martha K.	ASSOCIATE	810.00	Communication with J. Rorem (Legalpeople) regarding availability of reviewers over holiday weeks.	0.2	162.00
12/16/2019	Harrison, Martha K.	ASSOCIATE	810.00	Communication with K. McDonald regarding request for contract attorneys.	0.1	81.00
12/16/2019	Hancock, Anne F.	ASSOCIATE	770.00	Revise and finalize production letter and documents to be produced to the DOJ.	0.6	462.00
12/16/2019	Hancock, Anne F.	ASSOCIATE	770.00	Correspondence regarding additional searches to identify potentially responsive documents to SEC chronology for DOJ production.	0.3	231.00
12/16/2019	Hancock, Anne F.	ASSOCIATE	770.00	Meet with D. O'Connor to discuss production and status of document review and collection for DOJ production.	0.5	385.00
12/16/2019	Hancock, Anne F.	ASSOCIATE	770.00	Call with M. Nevin to discuss production and plan for document review regarding SEC chronology.	0.3	231.00
12/16/2019	Hancock, Anne F.	ASSOCIATE	770.00	Meet with D. O'Connor to prepare for call with the DOJ regarding document review.	0.2	154.00
12/16/2019	McDonald, Katherine	ASSOCIATE	550.00	Call with M. Nevin.	0.3	165.00
12/16/2019	McDonald, Katherine	ASSOCIATE	550.00	Revise and finalize production letter and document production.	2.1	1,155.00
12/16/2019	McDonald, Katherine	ASSOCIATE	550.00	Correspond with M. Harrison regarding use of contract attorneys for upcoming document review.	0.2	110.00
12/16/2019	Eagon, Haley	ASSOCIATE	485.00	Analyze document hit counts for various search term combinations.	0.4	194.00
12/16/2019	Eagon, Haley	ASSOCIATE	485.00	Attend and take notes regarding client call.	0.4	194.00
12/16/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Call with M. Nevin, S. Meyers, D. O'Connor and A. Hancock regarding document review strategy.	0.4	170.00
12/16/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review document production settings with K. McDonald and C. Evans.	0.6	255.00
12/16/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussions with K. McDonald regarding potential document review staffing.	0.4	170.00
12/16/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review search term and custodial hit count reporting circulated by C. Evans.	0.3	127.50
12/16/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team in preparing documents in anticipation of production.	0.5	160.00
12/16/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team by generating metrics to assist in their review of client data set.	2.5	800.00
12/16/2019	Albert-Rozenberg, Daniel	PARALEGAL	235.00	Prepare document production.	0.5	117.50
12/17/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Review materials from initial review of materials from interactions with key board member and interactions with him as witness.	1	1,075.00
12/17/2019	Harrison, Martha K.	ASSOCIATE	810.00	Communication with K. McDonald regarding potential contract attorney review.	0.1	81.00
12/17/2019	Hancock, Anne F.	ASSOCIATE	770.00	Internal training on how to use DISCO document vendor.	0.5	385.00
12/17/2019	Hancock, Anne F.	ASSOCIATE	770.00	Draft and revise searches in response to amended DOJ document requests.	0.6	462.00
12/17/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review documents identified as potentially responsive with respect to A. Lavidas.	2	1,540.00
12/17/2019	McDonald, Katherine	ASSOCIATE	550.00	Review board materials to identify material responsive to the DOJ indictment.	2.8	1,540.00
12/17/2019	McDonald, Katherine	ASSOCIATE	550.00	Discuss DOJ subpoena and document review with D. O'Connor.	0.3	165.00
12/17/2019	McDonald, Katherine	ASSOCIATE	550.00	Internal training on how to use DISCO document vendor.	0.5	275.00
12/17/2019	McDonald, Katherine	ASSOCIATE	550.00	Review documents involving A. Lavidas for responsive material and summarize same.	3.2	1,760.00
12/17/2019	Eagon, Haley	ASSOCIATE	485.00	Confer with R&G team regarding upcoming document production, draft search terms corresponding to indictment summary, and review documents for responsiveness.	8.6	4,171.00
12/17/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Discussion with A. Hancock, C. Evans and CSDISCO regarding steps for producing documents out of hosted review platform.	0.4	170.00
12/17/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Provide case team with training on how to utilize external review platform to assist in their review.	0.8	256.00
12/17/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team in preparing document for review in external review platform.	2	640.00
12/18/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review documents identified as responsive with respect to A. Lavidas for potential production.	0.4	308.00
12/18/2019	Hancock, Anne F.	ASSOCIATE	770.00	Discuss DOJ document request and production with D. O'Connor.	0.3	231.00
12/18/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review documents identified as relevant to SEC chronology for potential production.	1.6	1,232.00
12/18/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review board materials identified as potentially relevant to the DOJ indictment and discuss same with K. McDonald.	1.8	1,386.00
12/18/2019	McDonald, Katherine	ASSOCIATE	550.00	Review and summarize documents identified as responsive with respect to A. Lavidas and Ariad Board for potential production.	3	1,650.00
12/18/2019	Eagon, Haley	ASSOCIATE	485.00	Conduct additional document review for responsiveness to SEC chronology entries, compile and summarize relevant documents.	7.6	3,686.00

**Ropes & Gray Fees**

Work Date	Name	Title	Agreed Rate	Narrative/ Cost Description	Billed Hours	Billed Amount
12/18/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Communications with A. Hancock and C. Evans regarding preparation of additional searches and document production population,	0.4	170.00
12/18/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Prepare documents in external review platform for review by case team.	0.3	96.00
12/18/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team by configuring external review platform to assist team in review of client data set.	1	320.00
12/18/2019	Albert-Rozenberg, Daniel	PARALEGAL	235.00	Review pulled documents for K. McDonald. Pull documents for H. Eagan.	0.7	164.50
12/19/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Review production letter and discuss same with team and review privilege log and materials related to communications with Board member	1.3	1,397.50
12/19/2019	Hancock, Anne F.	ASSOCIATE	770.00	Review documents identified as potentially responsive to SEC chronology for DOJ production.	0.3	231.00
12/19/2019	Hancock, Anne F.	ASSOCIATE	770.00	Finalize documents for production and discuss same with D. O'Connor.	1	770.00
12/19/2019	McDonald, Katherine	ASSOCIATE	550.00	Draft production letter to DOJ and finalize documents for production.	3.1	1,705.00
12/19/2019	Eagon, Haley	ASSOCIATE	485.00	Conclude review of documents responsive to SEC chronology entries for DOJ production, and prepare for review by A. Hancock and D. O'Connor.	0.7	339.50
12/19/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review document production process with CSDISCO and coordinate with C. Evans to export document production volume.	1.5	637.50
12/19/2019	Evans, Cameron	LIT SUPP ANALST	320.00	At the request of K. McDonald, process data set in internal review platform in preparation of production.	0.8	256.00
12/19/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team in preparing documents for production.	1.5	480.00
12/19/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Communicate with client's data hosting vendor to discuss work flow when using external review platform.	1.3	416.00
12/19/2019	Albert-Rozenberg, Daniel	PARALEGAL	235.00	Prepare materials for A. Hancock.	0.4	94.00
12/20/2019	O'Connor, R. Daniel	PARTNER	1,075.00	Review production materials	0.5	537.50
12/20/2019	Hancock, Anne F.	ASSOCIATE	770.00	Revise production letter to the DOJ and conduct quality control review of production.	2.1	1,617.00
12/20/2019	McDonald, Katherine	ASSOCIATE	550.00	Revise production letter and finalize document production to the DOJ.	2.3	1,265.00
12/20/2019	Malek, Gillian C	LIT SUPP ANALST	425.00	Review finalized production volumes and discuss same with C. Evans and case team.	0.6	255.00
12/20/2019	Evans, Cameron	LIT SUPP ANALST	320.00	Assist case team in preparing documents for the third and fourth production sets.	1.3	416.00
12/20/2019	Albert-Rozenberg, Daniel	PARALEGAL	235.00	Assist with production.	1.3	305.50
1/6/2020	McDonald, Katherine	ASSOCIATE	680.00	Monitor Lavidas trial updates and draft email to the client regarding same.	0.4	272.00
1/7/2020	Hancock, Anne F.	ASSOCIATE	865.00	Draft summary regarding trial developments.	0.7	605.50
1/8/2020	Hancock, Anne F.	ASSOCIATE	865.00	Draft trial update email.	0.3	259.50
1/8/2020	McDonald, Katherine	ASSOCIATE	680.00	Monitor Lavidas trial updates and draft email to the client regarding same.	0.4	272.00
1/8/2020	Eagon, Haley	ASSOCIATE	585.00	Set up daily alerts regarding docket and media updates in US v. Lavidas trial.	0.5	292.50
1/8/2020	Montesinos, Delia	OTHER PROFESS	330.00	BNA newsletter for H. Eagon	0.2	66.00
1/9/2020	Hancock, Anne F.	ASSOCIATE	865.00	Revise trial update email.	0.1	86.50
1/9/2020	Eagon, Haley	ASSOCIATE	585.00	Compile and review recent news on the Lavidas trial, and draft client update.	1.7	994.50
1/10/2020	Hancock, Anne F.	ASSOCIATE	865.00	Revise draft client update.	0.2	173.00
1/10/2020	McDonald, Katherine	ASSOCIATE	680.00	Monitor Lavidas trial updates and draft email to the client regarding same.	0.4	272.00
1/10/2020	Eagon, Haley	ASSOCIATE	585.00	Compile and review recent news on the Lavidas trial, and draft client update.	0.7	409.50
1/13/2020	Eagon, Haley	ASSOCIATE	585.00	Confer with client regarding trial update.	0.2	117.00
1/14/2020	McDonald, Katherine	ASSOCIATE	680.00	Monitor Lavidas trial updates and draft email to the client regarding same.	0.4	272.00
1/15/2020	Hancock, Anne F.	ASSOCIATE	865.00	Revise trial update.	0.2	173.00
1/15/2020	McDonald, Katherine	ASSOCIATE	680.00	Monitor Lavidas trial updates and draft email to the client regarding same.	0.3	204.00
1/16/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding litigation hold.	0.1	86.50
1/22/2020	Montesinos, Delia	OTHER PROFESS	330.00	Alert cancel for H. Eagon	0.1	33.00
2/13/2020	O'Connor, R. Daniel	PARTNER	1,145.00	Discuss plan to submit fee application with A. Hancock and email with AUSA and client	0.5	572.50
2/14/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding fee application.	0.1	86.50
2/14/2020	Eagon, Haley	ASSOCIATE	585.00	Review relevant court deadlines and confer with paralegal team about docket tracking.	0.3	175.50
2/14/2020	Albert-Rozenberg, Daniel	PARALEGAL	250.00	Calendar US v Lavidas court dates, and track dockets for K. McDonald.	0.5	125.00
2/18/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding fee request.	0.1	86.50
2/25/2020	O'Connor, R. Daniel	PARTNER	1,145.00	Call with client regarding submission for fees in restitution matter in sentencing.	0.3	343.50
2/25/2020	Hancock, Anne F.	ASSOCIATE	865.00	Call regarding fee application.	0.5	432.50
2/26/2020	Hancock, Anne F.	ASSOCIATE	865.00	Call R. Cooper regarding fee submission.	0.1	86.50
2/28/2020	O'Connor, R. Daniel	PARTNER	1,145.00	Call with DOJ on plan for request for fees.	0.3	343.50
2/28/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding fee application submission.	0.2	173.00

**Ropes & Gray Fees**

Work Date	Name	Title	Agreed Rate	Narrative/ Cost Description	Billed Hours	Billed Amount
3/8/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding fee application.	0.1	86.50
3/9/2020	Eagon, Haley	ASSOCIATE	585.00	Confer with S. Grannemann regarding fee submission letter, and conduct 2nd Circuit legal research regarding the same.	1.8	1,053.00
3/9/2020	Grannemann, Scott	ASSOCIATE	585.00	Attend phone call with H. Eagon to discuss victim restitution rights under the Mandatory Victim's Resituation Act.	0.6	351.00
3/10/2020	Eagon, Haley	ASSOCIATE	585.00	Conduct additional legal research and begin drafting fee submission letter.	2.1	1,228.50
3/11/2020	Eagon, Haley	ASSOCIATE	585.00	Finalize first draft of fee submission letter for review by A. Hancock.	1.7	994.50
3/12/2020	Eagon, Haley	ASSOCIATE	585.00	Confer with litigation technology team regarding details of DOJ production, for insertion into fee submission letter.	0.1	58.50
3/12/2020	Evans, Cameron	LIT SUPP ANALST	330.00	Generate metrics to assist case team in review of production data.	1.3	429.00
3/12/2020	Harry, Saron	PARALEGAL	330.00	Review production history and report out volumes 1-4 production metrics to team.	0.2	66.00
3/16/2020	O'Connor, R. Daniel	PARTNER	1,145.00	Discuss restitution plan with A Hancock and client	0.4	458.00
3/16/2020	Hancock, Anne F.	ASSOCIATE	865.00	Call with M. Nevin regarding fee restitution request.	0.3	259.50
3/16/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email with government regarding fee restitution submission.	0.2	173.00
3/16/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding draft fee application submission.	0.3	259.50
3/16/2020	Eagon, Haley	ASSOCIATE	585.00	Update internal reminder regarding fee submission deadline.	0.1	58.50
3/17/2020	Hancock, Anne F.	ASSOCIATE	865.00	Revise draft letter and email regarding Gibson Dunn fees.	1	865.00
3/17/2020	Eagon, Haley	ASSOCIATE	585.00	Analyze action items with A. Hancock regarding fee submission.	0.2	117.00
3/17/2020	Eagon, Haley	ASSOCIATE	585.00	Conduct database research and review shared drive regarding relevant subpoenas	0.3	175.50
3/20/2020	O'Connor, R. Daniel	PARTNER	1,145.00	Email Gibson with request on legal fees	0.3	343.50
3/20/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding restitution request.	0.2	173.00
3/23/2020	McDonald, Katherine	ASSOCIATE	680.00	Revise restitution letter.	0.9	612.00
3/23/2020	Eagon, Haley	ASSOCIATE	585.00	Update draft letter regarding restitution request.	0.8	468.00
3/24/2020	Hancock, Anne F.	ASSOCIATE	865.00	Revise draft letter to the court.	1	865.00
3/24/2020	McDonald, Katherine	ASSOCIATE	680.00	Revise restitution letter.	0.8	544.00
3/24/2020	Eagon, Haley	ASSOCIATE	585.00	Revise draft restitution letter.	1	585.00
3/25/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding invoices.	0.2	173.00
3/25/2020	Hancock, Anne F.	ASSOCIATE	865.00	Revise letter and email regarding submission extension.	0.7	605.50
3/25/2020	Eagon, Haley	ASSOCIATE	585.00	Confer with litigation technology and paralegal teams regarding finalizing details of letter requesting restitution.	1.2	702.00
3/25/2020	Malek, Gillian C	LIT SUPP ANALST	330.00	Compile email collection and production metrics, per A. Hancock, K. McDonald and H. Eagon.	0.7	231.00
3/26/2020	Albert-Rosenberg, Daniel	PARALEGAL	250.00	Recalendar trial dates per H. Eagon's instructions.	0.3	75.00
3/27/2020	O'Connor, R. Daniel	PARTNER	1,145.00	Review and revise letter seeking restitution and discuss same with team, exchange emails with A Hancock on data for restitution request to Gibson.	0.7	801.50
3/27/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding request deadline and Gibson invoices.	0.2	173.00
3/27/2020	McDonald, Katherine	ASSOCIATE	680.00	Revise restitution letter and draft victim impact statement.	0.8	544.00
3/27/2020	Eagon, Haley	ASSOCIATE	585.00	Confer with R&G team regarding ongoing action items.	0.1	58.50
3/30/2020	Hancock, Anne F.	ASSOCIATE	865.00	Finalize letter brief and victim response letter.	1.2	1,038.00
3/30/2020	McDonald, Katherine	ASSOCIATE	680.00	Revise restitution letter and draft victim impact statement.	0.4	272.00
3/30/2020	Eagon, Haley	ASSOCIATE	585.00	Draft victim impact statement for review by D. O'Connor.	1.6	936.00
3/31/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding restitution request and finalize same.	0.5	432.50
4/1/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding letter brief and invoices.	0.2	173.00
4/2/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email regarding restitution submission and revise same.	0.6	519.00
4/2/2020	Hancock, Anne F.	ASSOCIATE	865.00	Email with M. Nevin and DOJ regarding restitution request.	0.3	259.50
4/2/2020	Eagon, Haley	ASSOCIATE	585.00	Update calendar notifications regarding delayed sentencing.	0.2	117.00
5/20/2020	O'Connor, R. Daniel	PARTNER	1,145.00	Email with A Hancock about gathering evidence for submission to court on fee request.	0.2	229.00
5/20/2020	Hancock, Anne F.	ASSOCIATE	865.00	Correspondence regarding fee request submission.	0.4	346.00
5/20/2020	Eagon, Haley	ASSOCIATE	585.00	Confer with billing department regarding recent client invoices.	0.2	117.00
5/21/2020	Eagon, Haley	ASSOCIATE	585.00	Review invoices and propose redactions for fee reimbursement submission.	1.1	643.50
5/28/2020	Hancock, Anne F.	ASSOCIATE	865.00	Finalize fee request and exhibits.	0.6	519.00
5/28/2020	Eagon, Haley	ASSOCIATE	585.00	Review additional invoices and propose redactions for fee reimbursement submission.	1.3	760.50
5/29/2020	Hancock, Anne F.	ASSOCIATE	865.00	Revise fee application exhibits and email regarding same.	0.3	259.50
5/29/2020	Eagon, Haley	ASSOCIATE	585.00	Prepare R&G time entries for submission	1.1	643.50
5/30/2020	Eagon, Haley	ASSOCIATE	585.00	Prepare R&G time entries for submission	0.4	234.00

Fee Total \$145,224.00

# Exhibit 3

Gibson, Dunn & Crutcher LLP

## Gibson Dunn Fees

Work Date	Name	Title	Agreed Rate	Narrative / Cost Description	Billed Hours / Units	Billed Amount
1/31/2017			17,378.38	VENDOR: MINTZ GROUP LLC INVOICE#: 352293 DATE: 1/31/2017 Outside Services/Consultants/Fees and expenses.	1	17,378.38
3/1/2017	Brodsky,Reed	Partner	1,155.00	Prepare revisions to draft letter to USAO; email to GDC team re same; email exchanges with GDC team re same.	0.7	808.50
3/1/2017	Brodsky,Reed	Partner	1,155.00	Prepare revisions to draft letter to USAO.	0.03	34.65
3/1/2017	Brodsky,Reed	Partner	1,155.00	Email to GDC team re same.	0.03	34.65
3/1/2017	Brodsky,Reed	Partner	1,155.00	Email exchanges with GDC team re same.	0.04	46.20
3/16/2017			15.25	IN HOUSE DUPLICATION - 03/16/2017, JOB TICKET #4685, REQUESTOR: B. GARMYN, 75 REGULAR TAB(S), 1 D-RING-1 1/2 BINDER(S), J. WIRCHIN	1	15.25
3/21/2017			31.50	IN HOUSE DUPLICATION - 03/21/2017, JOB TICKET #4985, REQUESTOR: B. GARMYN, 150 REGULAR TAB(S), 2 D-RING-2 BINDER(S), J. WIRCHIN	1	31.50
3/24/2017			35.21	VENDOR: FEDERAL EXPRESS CORPORATION INVOICE#: FEDX-20170331 DATE: 3/31/2017 Ship Date 03/24/2017 Airbill No: 778740391219 From: MARK CHERRY, Gibson Dunn & Crutcher LLP, NEW YORK, NY To: AIMEE HECTOR, UNITED STATES ATTORNEYS OFFICE, NEW YORK, NY	1	35.21
3/24/2017			16.06	IN HOUSE DUPLICATION - 03/24/2017, JOB TICKET #5277, REQUESTOR: B. GARMYN, 2 LABEL(S), 2 DVD(S), J. WIRCHIN	1	16.06
3/31/2017			45.75	IN HOUSE DUPLICATION - 03/31/2017, JOB TICKET #4985, REQUESTOR: B.GARMYN, 225 REGULAR TAB(S), 3 D-RING-1 1/2 BINDER(S), J. WIRCHIN	1	45.75
4/4/2017	Reilly,Brittany	Associate	775.00	Confer with J. Halperin regarding document production.	0.3	232.50
4/13/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails; meet and confer with M. Cherry to review privilege designations.	0.6	543.00
4/13/2017	Cherry,Mark	Associate	605.00	Meet with J. Halperin to discuss privilege document review; draft email to Ryan regarding privilege document review; locate Ariad's insider trading policies.	0.9	544.50
4/14/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails.	0.3	271.50
4/18/2017	Reilly,Brittany	Associate	775.00	Review and analyze documents for privilege.	1.7	1,317.50
4/18/2017	Cherry,Mark	Associate	605.00	Discuss privileged emails with B. garmyn; review potentially privileged emails.	0.1	60.50
4/19/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails.	0.1	90.50
4/19/2017	Reilly,Brittany	Associate	775.00	Review and analyze documents for privilege.	0.8	620.00
4/19/2017	Cherry,Mark	Associate	605.00	Review and collect insider trading policies.	0.3	181.50
4/25/2017			248.82	APRIL_2017-EDISCOVERY_DATABASE_HOSTING_FEES-C/M_04829-00003-(MONTHLY_EDISCOVERY_DATABASE_HOSTING_FEES)	1	248.82
4/25/2017		-		Fee Adjustment: Premium Discount	0	(239.28)
5/1/2017	Reilly,Brittany	Associate	775.00	Confer with J. Halperin regarding production status.	0.2	155.00
5/3/2017	Reilly,Brittany	Associate	775.00	Confer with J. Halperin regarding subpoena response.	0.1	77.50
5/4/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails; meet and confer with M. Cherry re response to USAO.	0.2	181.00
5/4/2017	Reilly,Brittany	Associate	775.00	Review FINRA request.	0.2	155.00
5/8/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails; telephone conference with B. Garmyn re response to USAO.	0.2	181.00
5/8/2017	Reilly,Brittany	Associate	775.00	Draft production cover letter; telephone conference with J. Halperin regarding production.	0.5	387.50
5/9/2017	Reilly,Brittany	Associate	775.00	Confer with R. Brodsky and J. Halperin regarding production.	0.1	77.50
5/11/2017	Reilly,Brittany	Associate	775.00	Review FINRA request and confer with M. Hewett regarding same.	0.3	232.50
5/12/2017	Reilly,Brittany	Associate	775.00	Review and analyze privileged documents and confer with R. Brodsky regarding same.	1.3	1,007.50
5/12/2017			0.10	In House Duplication Charge via Equitrac - 05/12/2017	8	0.80
5/12/2017			0.10	In House Duplication Charge via Equitrac - 05/12/2017	8	0.80
5/12/2017			0.10	In House Duplication Charge via Equitrac - 05/12/2017	46	4.60
5/12/2017			0.10	In House Duplication Charge via Equitrac - 05/12/2017	6	0.60
5/12/2017			0.10	In House Duplication Charge via Equitrac - 05/12/2017	48	4.80
5/18/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails.	0.1	90.50
5/18/2017	Reilly,Brittany	Associate	775.00	Confer with R. Brodsky and J. Halperin regarding potentially privileged documents.	0.2	155.00
5/19/2017	Reilly,Brittany	Associate	775.00	Confer with M. Hewitt regarding FINRA response.	0.8	620.00
5/20/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails.	0.1	90.50
5/20/2017	Reilly,Brittany	Associate	775.00	Review privileged documents and confer with J. Halperin regarding same.	0.4	310.00
5/23/2017	Reilly,Brittany	Associate	775.00	Perform QC of production.	8.1	6,277.50
5/24/2017	Reilly,Brittany	Associate	775.00	Perform document production QC.	1.6	1,240.00
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	1	0.10
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	4	0.40

**Gibson Dunn Fees**

Work Date	Name	Title	Agreed Rate	Narrative / Cost Description	Billed Hours / Units	Billed Amount
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	3	0.30
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	6	0.60
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	7	0.70
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	2	0.20
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	10	1.00
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	46	4.60
5/24/2017			0.10	In House Duplication Charge via Equitrac - 05/24/2017	5	0.50
5/25/2017			248.82	MAY_2017-EDISCOVERY_DATABASE_HOSTING_FEES-C/M_04829-00003-(MONTHLY_EDISCOVERY_DATABASE_HOSTING_FEES)	1	248.82
5/25/2017			-	Fee Adjustment: Premium Discount	0	(561.90)
6/6/2017	Halperin,Jason	Of Counsel	905.00	Telephone conference with B. Garmyn about latest production to U.S. Attorney's Office; review documents re same.	0.7	633.50
6/6/2017	Reilly,Brittany	Associate	775.00	Confer multiple times with litigation support regarding production; revise and edit production cover letter; perform QC regarding production.	4.3	3,332.50
6/6/2017	Roymisher,Leonid	OT	405.00	Analyze and quality check the data for production; process files into tiff images; extract the production files; review production data set for consistency.	2.7	1,093.50
6/7/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails.	0.1	90.50
6/7/2017	Reilly,Brittany	Associate	775.00	Revise and edit production cover letter; confer with J. Halperin and litigation support regarding production; finalize production.	1.5	1,162.50
6/7/2017	Cherry,Mark	Associate	605.00	Prepare and produce documents to United States Attorney's Office.	0.3	181.50
6/7/2017	Roymisher,Leonid	OT	405.00	Update custom fields required by DOJ; encrypt data set for transmission; Extract and load data on the requested media	1.4	567.00
6/7/2017			24.75	VENDOR: DELUXE DELIVERY SYSTEMS, INC. INVOICE#: 240795 DATE: 6/11/2017 Ticket# W1393505 06/07/2017 From GIBSON DUNN & CRUTCHER, 200 PARK AVENUE, NEW YORK, NY 10166 To UNITED STATES ATTORNEY'S OFFICE, ONE ST. ANDREW'S PLAZA, NEW YORK, NY 10007 MARK CHERRY	1	24.75
6/8/2017	Halperin,Jason	Of Counsel	905.00	Prepare, review, and respond to e-mails; telephone conference with B. Garmyn re latest production; telephone conference with SDNY AUSA A. Hector re latest production.	0.5	452.50
6/8/2017	Reilly,Brittany	Associate	775.00	Telephone conferences with J. Halperin and AUSA Hector regarding production; draft emails regarding production.	0.7	542.50
6/27/2017			270.98	JUNE_2017-EDISCOVERY_DATABASE_HOSTING_FEES-C/M_04829-00003-(MONTHLY_EDISCOVERY_DATABASE_HOSTING_FEES)	1	270.98
6/27/2017			-	Fee Adjustment: Premium Discount	0	(406.85)
						<b>Fee Total \$41,206.99</b>